Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 40
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cofactors facilitate bona fide prion misfolding in vitro but are not necessary for the infectivity of recombinant murine prions

  • Pérez-Castro, Miguel Ángel
  • Eraña, Hasier|||0000-0001-8776-4211
  • Vidal Barba, Enric|||0000-0002-4965-3286
  • Charco, Jorge M.|||0000-0003-3476-1855
  • Lorenzo, Nuria L.
  • Gonçalves-Anjo, Nuno|||0000-0003-0586-2550
  • Galarza-Ahumada, Josu|||0000-0003-0275-559X
  • Díaz-Domínguez, Carlos M.|||0000-0002-0410-1963
  • Piñeiro, Patricia|||0000-0002-0062-2542
  • González-Miranda, Ezequiel
  • Giler, Samanta
  • Telling, Glenn
  • Sánchez-Martín, Manuel A.|||0000-0001-8370-1336
  • Garrido, Joseba M.
  • Geijo, Maria V.|||0000-0002-3120-1038
  • Requena, Jesús R.
  • Castilla, Joaquín|||0000-0002-2216-1361
Prion diseases, particularly sporadic cases, pose a challenge due to their complex nature and heterogeneity. The underlying mechanism of the spontaneous conversion from PrP C to PrP Sc, the hallmark of prion diseases, remains elusive. To shed light on this process and the involvement of cofactors, we have developed an in vitro system that faithfully mimics spontaneous prion misfolding using minimal components. By employing this PMSA methodology and introducing an isoleucine residue at position 108 in mouse PrP, we successfully generated recombinant murine prion strains with distinct biochemical and biological properties. Our study aimed to explore the influence of a polyanionic cofactor in modulating strain selection and infectivity in de novo -generated synthetic prions. These results not only validate PMSA as a robust method for generating diverse bona fide recombinant prions but also emphasize the significance of cofactors in shaping specific prion conformers capable of crossing species barriers. Interestingly, once these conformers are established, our findings suggest that cofactors are not necessary for their infectivity. This research provides valuable insights into the propagation and maintenance of the pathobiological features of cross-species transmissible recombinant murine prion and highlights the intricate interplay between cofactors and prion strain characteristics. Prion diseases are rare and complex neurodegenerative disorders that can occur spontaneously, through a poorly understood conformational or structural change of normal, physiological prion protein. This abnormally structured form, known as prion, acquires the capacity to induce the same transformation to surrounding prion proteins, leading to disease. In our study, we take advantage of a recently developed methodology that closely mimics this process in a test tube using extremely simple components. Applying this system and modifying a specific part of the mouse prion protein, we were able to generate different prion strains with unique characteristics spontaneously. This process is greatly enhanced using an additional molecule called cofactor, that has been proposed to affect the variability and infectivity (capacity to cause disease in an animal model) of these prions. Our findings show that while cofactors facilitate the spontaneous formation of prions and may influence their final characteristics, they are not necessary for their infectivity nor for their spontaneous formation. This research gives new insights into the role cofactors play in the spontaneous generation of prions and their behavior in animal models.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exploring Glycan-Lectin Interactions in Natural-Like Environments, A View Using NMR Experiments Inside Cell and on Cell Surface

  • Bertuzzi, Sara
  • Lete, Marta G.
  • Franconetti, Antonio|||0000-0002-7972-8795
  • Diercks, Tammo
  • Delgado, Sandra
  • Oyenarte, Iker
  • Moure Garcia, Maria Jesus|||0000-0001-5120-2460
  • Núñez Franco, Reyes|||0000-0002-7148-9099
  • Valverde, Pablo|||0000-0002-0398-5883
  • Lenza, Maria Pia
  • Sobczak, Klaudia
  • Jiménez-Osés, Gonzalo|||0000-0003-0105-4337
  • Paulson, James C.|||0000-0003-4589-5322
  • Ardá, Ana
  • Ereño-Orbea, June|||0000-0002-5076-2105
  • Jiménez Barbero, Jesús|||0000-0001-5421-8513
Glycan-mediated molecular recognition events are essential for life. NMR is widely used to monitor glycan binding to lectins in solution using isolated glycans and lectins. In this context, we herein explore diverse NMR methodologies, from both the receptor and ligand perspectives, to monitor glycan-lectin interactions under experimental conditions mimicking the native milieu inside cells and on cell surface. For the NMR experiments inside cells, galectin-7 is employed as model, since most galectins are soluble and carry out their functions in the cellular micro-environment. Using Danio Rerio oocytes, the 1H-15N HMQC NMR spectrum of a folded galectin has been observed inside cell for the first time, using a glycomimetic ligand (TDG) to overcoming the natural tendency of galectins to bind to numerous galactose-containing receptors within cells. Alternatively, most lectins, other than galectins, are displayed on the cell surface, providing a multivalent presentation to bind their glycan partners in cis (at the same cell) or in trans (on other cells). In this case, ligand-based STD-NMR experiments have been successfully applied to account for the interactions of natural glycans and glycomimetics with Siglec-10. These methodologies provide the proof-of-concept to open the door to the NMR analysis of the recognition of glycans in native-like settings.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Unprecedented selectivity for homologous lectin targets, differential targeting of the viral receptors L-SIGN and DC-SIGN

  • Delaunay, Clara
  • Pollastri, Sara
  • Thepaut, Michel
  • Cavazzoli, Gianluca
  • Belvisi, Laura
  • Bouchikri, Clementine
  • Labiod, Nuria
  • Lasala, Fatima
  • Gimeno, Ana
  • Franconetti, Antonio|||0000-0002-7972-8795
  • Jiménez Barbero, Jesús|||0000-0001-5421-8513
  • Arda, Ana
  • Delgado, Rafael
  • Bernardi, Anna
  • Fieschi, Franck
DC-SIGN (CD209) and L-SIGN (CD209L) are two C-type lectin receptors (CLRs) that facilitate SARS-CoV-2 infections as viral co-receptors. SARS-CoV-2 manipulates both DC-SIGN and L-SIGN for enhanced infection, leading to interest in developing receptor antagonists. Despite their structural similarity (82% sequence identity), they function differently. DC-SIGN, found in dendritic cells, shapes the immune response by recognizing pathogen-associated carbohydrate patterns. In contrast, L-SIGN, expressed in airway epithelial endothelial cells, is not directly involved in immunity. COVID-19's primary threat is the hyperactivation of the immune system, potentially reinforced if DC-SIGN engages with exogenous ligands. Therefore, L-SIGN, co-localized with ACE2-expressing cells in the respiratory tract, is a more suitable target for anti-adhesion therapy. However, designing a selective ligand for L-SIGN is challenging due to the high sequence identity of the Carbohydrate Recognition Domains (CRDs) of the two lectins. We here present Man84, a mannose ring modified with a methylene guanidine triazole at position 2. It binds L-SIGN with a KD of 12.7μM ± 1 μM (ITC) and is the first known L-SIGN selective ligand, showing 50-fold selectivity over DC-SIGN (SPR). The X-ray structure of the L-SIGN CRD/Man84 complex reveals the guanidinium group's role in achieving steric and electrostatic complementarity with L-SIGN. This allows us to trace the source of selectivity to a single amino acid difference between the two CRDs. NMR analysis confirms the binding mode in solution, highlighting Man84's conformational selection upon complex formation. Dimeric versions of Man84 achieve additional selectivity and avidity in the low nanomolar range. These compounds selectively inhibit L-SIGN dependent trans-infection by SARS-CoV-2 and Ebola virus. Man84 and its dimeric constructs display the best affinity and avidity reported to date for low-valency glycomimetics targeting CLRs. They are promising tools for competing with SARS-CoV-2 anchoring in the respiratory tract and have potential for other medical applications.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Unraveling Molecular Recognition of Glycan Ligands by Siglec-9 via NMR Spectroscopy and Molecular Dynamics Modeling

  • Atxabal, Unai|||0000-0002-0546-8521
  • Nycholat, Corwin
  • Pröpster, Johannes M.
  • Fernández, Andrea
  • Oyenarte, Iker
  • Lenza, Maria Pia
  • Franconetti, Antonio|||0000-0002-7972-8795
  • Soares, Cátia O.
  • Coelho, Helena|||0000-0003-1992-8557
  • Marcelo, Filipa
  • Schubert, Mario|||0000-0003-0278-4091
  • Paulson, James C.|||0000-0003-4589-5322
  • Jiménez Barbero, Jesús|||0000-0001-5421-8513
  • Ereño-Orbea, June|||0000-0002-5076-2105
Human sialic-acid-binding immunoglobulin-like lectin-9 (Siglec-9) is a glycoimmune checkpoint receptor expressed on several immune cells. Binding of Siglec-9 to sialic acid containing glycans (sialoglycans) is well documented to modulate its functions as an inhibitory receptor. Here, we first assigned the amino acid backbone of the Siglec-9 V-set domain (Siglec-9d1), using well-established triple resonance three-dimensional nuclear magnetic resonance (NMR) methods. Then, we combined solution NMR and molecular dynamic simulation methods to decipher the molecular details of the interaction of Siglec-9 with the natural ligands α2,3 and α2,6 sialyl lactosamines (SLN), sialyl Lewis X (sLeX), and 6-O sulfated sLeX and with two synthetically modified sialoglycans that bind with high affinity. As expected, Neu5Ac is accommodated between the F and G β-strands at the canonical sialic acid binding site. Addition of a heteroaromatic scaffold 9N-5-(2-methylthiazol-4-yl)thiophene sulfonamide (MTTS) at the C9 position of Neu5Ac generates new interactions with the hydrophobic residues located at the G-G' loop and the N-terminal region of Siglec-9. Similarly, the addition of the aromatic substituent (5-N-(1-benzhydryl-1H-1,2,3-triazol-4-yl)methyl (BTC)) at the C5 position of Neu5Ac stabilizes the conformation of the long and flexible B'-C loop present in Siglec-9. These results expose the underlying mechanism responsible for the enhanced affinity and specificity for Siglec-9 for these two modified sialoglycans and sheds light on the rational design of the next generation of modified sialoglycans targeting Siglec-9.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dissecting Tin-Based Activation and Anomerization Pathways in Carbohydrate Chemistry

  • Navo, Claudio Daniel|||0000-0003-0161-412X
  • Moure Garcia, Maria Jesus|||0000-0001-5120-2460
  • Valverde, Pablo|||0000-0002-0398-5883
  • Poveda, Ana|||0000-0001-5060-2307
  • Jiménez-Osés, Gonzalo|||0000-0003-0105-4337
  • Jiménez Barbero, Jesús|||0000-0001-5421-8513
  • Franconetti, Antonio|||0000-0002-7972-8795
Tin-based Lewis acids are widely used in glycosylation chemistry, but their precise mechanistic role is still not fully understood. In this study, we combine 119Sn NMR spectroscopy and density functional theory (DFT) calculations to investigate how Sn-(IV) promoters interact with glycosyl donors and influence anomerization. Our results indicate that glycosyl oxocarbenium ions can form stable ion pairs with tin-based counterions, underscoring the relevance of these species in glycosylation processes. The agreement between experimental and computed 119Sn chemical shifts provides structural insights into the coordination environment of the tin species. For anomerization, DFT energy profiles support a mechanism involving endocyclic C-O bond cleavage, rotation, and subsequent ring closure. These findings refine our understanding of tin-mediated transformations and offer a framework for rational design of Lewis acid promoters in glycochemistry.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

SUMOylation modulates eIF5A activities in both yeast and pancreatic ductal adenocarcinoma cells

  • Seoane, Rocío
  • Lama-Díaz, Tomás
  • Romero, Antonia María
  • El Motiam, Ahmed
  • Vidal, Santiago
  • Bouzaher, Yanis H.
  • Blanquer, María
  • Tolosa, Rocío M.
  • Castillo Mewa, Juan
  • Rodríguez, Manuel S.
  • García-Sastre, Adolfo
  • Xirodimas, Dimitris
  • Sutherland, James D.
  • Barrio, Rosa
  • Alepuz, Paula
  • Blanco, Miguel G.
  • Farràs, Rosa
  • Rivas, Carmen
  • Martínez-Férriz, Arantxa|||0000-0001-7193-2575
[EN] BackgroundThe eukaryotic translation initiation protein eIF5A is a highly conserved and essential factor that plays a critical role in different physiological and pathological processes including stress response and cancer. Different proteomic studies suggest that eIF5A may be a small ubiquitin-like modifier (SUMO) substrate, but whether eIF5A is indeed SUMOylated and how relevant is this modification for eIF5A activities are still unknown.MethodsSUMOylation was evaluated using in vitro SUMOylation assays, Histidine-tagged proteins purification from His6-SUMO2 transfected cells, and isolation of endogenously SUMOylated proteins using SUMO-binding entities (SUBES). Mutants were engineered by site-directed mutagenesis. Protein stability was measured by a cycloheximide chase assay. Protein localization was determined using immunofluorescence and cellular fractionation assays. The ability of eIF5A1 constructs to complement the growth of Saccharomyces cerevisiae strains harboring thermosensitive mutants of a yeast EIF5A homolog gene (HYP2) was analyzed. The polysome profile and the formation of stress granules in cells expressing Pab1-GFP (a stress granule marker) by immunofluorescence were determined in yeast cells subjected to heat shock. Cell growth and migration of pancreatic ductal adenocarcinoma PANC-1 cells overexpressing different eIF5A1 constructs were evaluated using crystal violet staining and transwell inserts, respectively. Statistical analysis was performed with GraphPad Software, using unpaired Student's t-test, or one-way or two-way analysis of variance (ANOVA).ResultsWe found that eIF5A is modified by SUMO2 in vitro, in transfected cells and under endogenous conditions, revealing its physiological relevance. We identified several SUMO sites in eIF5A and found that SUMOylation modulates both the stability and the localization of eIF5A in mammalian cells. Interestingly, the SUMOylation of eIF5A responds to specific stresses, indicating that it is a regulated process. SUMOylation of eIF5A is conserved in yeast, the eIF5A SUMOylation mutants are unable to completely suppress the defects of HYP2 mutants, and SUMOylation of eIF5A is important for both stress granules formation and disassembly of polysomes induced by heat-shock. Moreover, mutation of the SUMOylation sites in eIF5A abolishes its promigratory and proproliferative activities in PANC-1 cells.ConclusionsSUMO2 conjugation to eIF5A is a stress-induced response implicated in the adaptation of yeast cells to heat-shock stress and required to promote the growth and migration of pancreatic ductal adenocarcinoma cells., Open Access funding was provided thanks to the CRUE-CSIC agreement with Springer Nature. Funding at the laboratory of CR is provided by the Ministry of Science, Innovation and Universities and FEDER (BFU-2017-88880-P, PID2021-126510NBI00), and by the Xunta de Galicia (ED431G 2023/10). RS, SV and TLD are predoctoral fellows funded by the Xunta de Galicia – Consellería de Cultura, Educación y Ordenación Universitaria (ED481A-2020/160, ED481A-2018/110, and ED481A-2018/042, respectively). AMR is a postdoctoral fellow funded by the Generalitat Valenciana (CIAPOS2021/117). MB is a predoctoral fellow funded by Banco Santander and the University of Santiago de Compostela. RMT is a predoctoral fellow funded by the Instituto de Investigación Sanitaria de Santiago de Compostela. The Blanco lab is supported by MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2020-115472GB-I00) and by the Xunta de Galicia/FEDER – Una manera de hacer Europa (ED431C 2019/013). The RF lab is supported by the Fondo de Investigación Sanitaria, ISCIII (PI20-00194). The PA lab is supported by MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2020-120066RB-I00) and by GVA CIAICO/2022/237. AMF is a predoctoral fellow funded by the Asociación Española Contra el Cáncer (AECC APRO 2018). RB and JDS thank MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2020-114178GB-I00, CEX2021-001136-S). Finally, CR, RF and RB acknowledge support from SAF2017-90900-REDT (UBIRed Program, Spain) and COST Action ProteoCure CA20113.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Iridium-Catalyzed ortho-Selective Borylation of Aromatic Amides Enabled by 5-Trifluoromethylated Bipyridine Ligands

  • Marcos-Atanes, Daniel
  • Vidal Vides, Cristian
  • Navo Najera, Claudio Daniel
  • Peccati, Francesca
  • Jiménez Osés, Gonzalo
  • Mascareñas Cid, José Luis
Iridium-catalyzed borylations of aromatic C−H bonds are highly attractive transformations because of the diversification possibilities offered by the resulting boronates. These transformations are best carried out using bidentate bipyridine or phenanthroline ligands, and tend to be governed by steric factors, therefore resulting in the competitive functionalization of meta and/or para positions. We have now discovered that a subtle change in the bipyridine ligand, namely, the introduction of a CF3 substituent at position 5, enables a complete change of regioselectivity in the borylation of aromatic amides, allowing the synthesis of a wide variety of ortho-borylated derivatives. Importantly, thorough computational studies suggest that the exquisite regio- and chemoselectivity stems from unusual outer-sphere interactions between the amide group of the substrate and the CF3-substituted aryl ring of the bipyridine ligand
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Understanding the key features of the spontaneous formation of bona fde prions through a novel methodology that enables their swift and consistent generation

  • Eraña, Hasier
  • Díaz‑Domínguez, Carlos M.
  • Charco, Jorge M.
  • Vidal, Enric
  • González‑Miranda, Ezequiel
  • Pérez‑Castro, Miguel A.
  • Piñeiro, Patricia
  • López‑Moreno, Rafael
  • Sampedro‑Torres‑Quevedo, Cristina
  • Fernández‑Veiga, Leire
  • Tasis‑Galarza, Juan
  • Lorenzo, Nuria L.
  • Santini‑Santiago, Aileen
  • Lázaro, Melisa
  • García‑Martínez, Sandra
  • Gonçalves‑Anjo, Nuno
  • San‑Juan‑Ansoleaga, Maitena
  • Galarza‑Ahumada, Josu
  • Fernández‑Muñoz, Eva
  • Giler, Samanta
  • Valle, Mikel
  • Telling, Glenn C.
  • Geijó, Mariví
  • Requena, Jesús R.
  • Castilla, Joaquín
Among transmissible spongiform encephalopathies or prion diseases afecting humans, sporadic forms such as spo‑ radic Creutzfeldt–Jakob disease are the vast majority. Unlike genetic or acquired forms of the disease, these idiopathic forms occur seemingly due to a random event of spontaneous misfolding of the cellular PrP (PrPC) into the patho‑ genic isoform (PrPSc). Currently, the molecular mechanisms that trigger and drive this event, which occurs in approximately one individual per million each year, remain completely unknown. Modelling this phenomenon in experimental settings is highly challenging due to its sporadic and rare occurrence. Previous attempts to model spontaneous prion misfolding in vitro have not been fully successful, as the spontaneous formation of prions is infre‑ quent and stochastic, hindering the systematic study of the phenomenon. In this study, we present the frst method that consistently induces spontaneous misfolding of recombinant PrP into bona fde prions within hours, providing unprecedented possibilities to investigate the mechanisms underlying sporadic prionopathies. By fne‑tuning the Pro‑ tein Misfolding Shaking Amplifcation method, which was initially developed to propagate recombinant prions, we have created a methodology that consistently produces spontaneously misfolded recombinant prions in 100% of the cases. Furthermore, this method gives rise to distinct strains and reveals the critical infuence of charged sur‑ faces in this process., The present work was partially funded by three different grants awarded by “Ministerio de Economía y Competitividad” (Spanish Government), grant numbers PID2021-122201OB-C21, PID2021-1222010B-C22 and PID2020-117465GB-I00, funded by MCIN/AEI/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), and by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S, also funded by MCIN/AEI/10.13039/501100011033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Overexpression of bank vole PrP(I109) in mice induces a spontaneous atypical prion disease with sex-dependent onset, early NfL elevation, and universal prion strain permissiveness

  • Eraña, Hasier
  • Vidal, Enric
  • Fernández-Borges, Natalia
  • Charco, Jorge M.
  • Díaz‑Domínguez, Carlos M.
  • Sampedro-Torres-Quevedo, Cristina
  • San-Juan-Ansoleaga, Maitena
  • Fernández-Muñoz, Eva
  • Galarza-Ahumada, Josu
  • Pérez-Castro, Miguel Ángel
  • Gonçalves-Anjo, Nuno
  • Piñeiro, Patricia
  • Pirisinu, Laura
  • Di Bari, Michele Angelo
  • Giler, Samanta
  • Raimondi, Ilaria
  • Espinosa, Juan Carlos
  • Vanni, Ilaria
  • D’Agostino, Claudia
  • Rodríguez-Cuesta, Juan
  • Pasetto, Laura
  • Bonetto, Valentina
  • González-Martín, Nora
  • Teijeira, Susana
  • Zou, Wen-Quan
  • Geijo, Mariví
  • Torres, Juan María
  • Chiesa, Roberto
  • Sánchez‑Martín, Manuel A.
  • Nonno, Romolo
  • Requena, Jesús R.
  • Castilla, Joaquín
Transgenic mice overexpressing bank vole prion protein with the isoleucine 109 polymorphism, TgVole(I109)4x, develop spontaneous neurodegenerative disease with sex-dependent onset, averaging 170 days in females and 200 days in males at terminal stage. The clinical and pathological features closely resemble Gerstmann-Sträussler-Scheinker syndrome (GSS), with characteristic ataxia, dysmetria, kyphosis, and prominent PrP plaques. Biochemical analysis reveals an atypical prion protein banding pattern with a distinctive low molecular weight band (7–10 kDa) following proteinase K digestion, similar to other atypical prion diseases such as small ruminants atypical scrapie (AS). Importantly, these spontaneously generated prions are highly infectious when passaged to mice expressing the same I109 polymorphism as well as to wild bank voles carrying the I109 polymorphism, but not to models expressing the methionine variant at this position, demonstrating the critical role of this specific polymorphism in atypical prion propagation. Temporal analysis reveals that infectious prions emerge significantly (2–3 months) before clinical signs appear, offering important insights into the pre-clinical phase of prion diseases. Serum neurofilament light chain levels increase significantly at 80 days of age, approximately 100 days before clinical onset, providing a wide therapeutic window with a reliable biomarker. The TgVole(I109)4× model exhibits extraordinary versatility in propagating diverse prion strains, showing remarkable susceptibility to atypical prions (including GSS and AS) with exceptionally short incubation periods, while maintaining the ability to efficiently propagate classical and recombinant prion strains. We present here a thoroughly characterized transgenic mouse model that spontaneously develops an atypical, bona fide prion disease with sex-related differences in disease onset. This model offers valuable insights into spontaneous and atypical prionopathies while demonstrating exceptional versatility for studying diverse prion strains and potential utility for evaluating therapeutic interventions when used with appropriate study designs that account for individual variability., The present work was partially funded by five different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21 granted to J.C., PID2021-1222010B-C22 granted to E.V., and PID2023-146146NB-I00 to J.C.E. funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), UE and PID2020-117465GB-I00 granted to J.R.R., funded by MICIU/AEI/https://doi.org/10.13039/501100011033. EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027) granted to J.C. and H.E. Additional support was provided by the Instituto de Salud Carlos III (ISCIII), grant numbers AC21_2/00024 (granted to J.C), and JPND-2023–1822-108 (granted to R.C.) as part of the JPND initiative JPND-2021–650-130. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to J.C., also funded by Ministerio de Ciencia e Innovación/AEI /https://doi.org/10.13039/501100011033. E.F.-M. received funding from Fundación Tatiana Pérez de Guzmán el Bueno, grant BN661-FTPGB-2023. Transgenic Facility, directed by M.A.S.-M., is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. This work also received funding from the Creutzfeldt-Jakob Disease Foundation—2022. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

A Protein Misfolding Shaking Amplificationbased method for the spontaneous generation of hundreds of bona fide prions

  • Eraña, Hasier
  • Sampedro-Torres-Quevedo, Cristina
  • Charco, Jorge M.
  • Díaz-Domínguez, Carlos M.
  • Peccati, Francesca
  • San-Juan-Ansoleaga, Maitena
  • Vidal, Enric
  • Gonçalves-Anjo, Nuno
  • Pérez-Castro, Miguel A.
  • González-Miranda, Ezequiel
  • Piñeiro, Patricia
  • Fernández-Veiga, Leire
  • Galarza-Ahumada, Josu
  • Fernández-Muñoz, Eva
  • Perez de Nanclares, Guiomar
  • Telling, Glenn
  • Geijo, Mariví
  • Jiménez-Osés, Gonzalo
  • Castilla, Joaquín
Prion diseases are a group of rapidly progressing neurodegenerative disorders caused by the misfolding of the endogenous prion protein (PrPC) into a pathogenic form (PrPSc). This process, despite being the central event underlying these disorders, remains largely unknown at a molecular level, precluding the prediction of new potential outbreaks or interspecies transmission incidents. In this work, we present a method to generate bona fide recombinant prions de novo, allowing a comprehensive analysis of protein misfolding across a wide range of prion proteins from mammalian species. We study more than 380 different prion proteins from mammals and classify them according to their spontaneous misfolding propensity and their conformational variability. This study aims to address fundamental questions in the prion research field such as defining infectivity determinants, interspecies transmission barriers or the structural influence of specific amino acids and provide invaluable information for future diagnosis and therapy applications., The authors would like to thank the following for their support: IKERBasque foundation, personnel from vivarium, IT service (in particular to Sara Gómez Ramos for her assistance with the PrPdex webpage), maintenance departments of CIC bioGUNE, Neiker and IRTA-CReSA. The authors would also like to acknowledge the work from past laboratory members of the Prion Research Lab from CIC bioGUNE, that despite not directly involved in the manuscript have contributed along the years to the development of all the methods and techniques currently used in the laboratory (specially to Tomás Barrio and Leire Hervá for their efforts at the initial and end stages of the work, respectively). Finally, we would like to thank Jesús R. Requena for always useful scientific discussions and advice. The present work was partially funded by different grants awarded by “Ministerio de Economía y Competitividad” (Spanish Government), grant numbers PID2021-122201OB-C21, PID2021-1222010BC22, PID2021-125946OB-I00 and IJC2020-045506-I, funded by MCIN/ AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), and by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, to J.C. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021- 001136-S, also funded by MCIN/AEI /10.13039/501100011033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

The L108I polymorphism in mouse prion protein drives spontaneous disease and enhances transmission of atypical and classical prion strains

  • Eraña, Hasier
  • Vidal, Enric
  • Fernández-Borges, Natalia
  • Charco, Jorge M
  • Díaz-Domínguez, Carlos M
  • Sampedro-Torres-Quevedo, Cristina
  • Galarza-Ahumada, Josu
  • Fernández-Muñoz, Eva
  • San-Juan-Ansoleaga, Maitena
  • Pérez-Castro, Miguel Ángel
  • Gonçalves-Anjo, Nuno
  • Piñeiro, Patricia
  • Giler, Samanta
  • González-Martín, Nora
  • Lorenzo, Nuria L.
  • Manero-Azua, Africa
  • de Nanclares, Guiomar P.
  • Geijo, Mariví
  • Sánchez-Martín, Manuel A
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion diseases are fatal neurodegenerative disorders that can be idiopathic, associated with genetic mutations, or acquired by infection with misfolded prion protein. We developed two complementary transgenic mouse models to investigate how the L108I substitution in mouse prion protein (PrP) influences spontaneous prion formation and transmission characteristics. The transgenic mouse model overexpressing the variant at approximately three times wild-type (WT) PrP levels (TgMo(L108I)3x) consistently developed a spontaneous neurodegenerative disorder between 219 and 536 days of age with 100% penetrance. This spontaneous disease exhibited biochemical and neuropathological characteristics of atypical prion disorders, featuring a distinctive 7–10 kDa protease-resistant PrP fragment and pathology comparable to small ruminants' atypical scrapie and certain forms of Gerstmann–Sträussler–Scheinker syndrome (GSS). In contrast, the knock-in model expressing the same variant at physiological levels (TgMo(L108I)1x) showed no spontaneous disease beyond 600 days, demonstrating that both the specific amino acid substitution and elevated expression levels are necessary for spontaneous prion formation. The spontaneously generated prions transmitted efficiently to models expressing the I108 variant and to Tga20 mice overexpressing WT PrP but encountered a robust transmission barrier toward WT mice, indicating strain-specific replication requirements. The TgMo(L108I)3x model demonstrated exceptional versatility as a universal acceptor for heterogeneous prion isolates, demonstrating superior efficiency in propagating atypical variants like GSS A117V (57 ± 0.6 days) and rapid propagation of classical scrapie-derived mouse prion strains, including Rocky Mountains Laboratory mouse prion strain (RML) (85 ± 3.8 days) and 22L (95 ± 1 days). Comparative analysis revealed that the L108I substitution differentially impacts strain propagation, with greater acceleration of RML (~33% shorter incubation) than 22L (~0.5% shorter) compared to WT mice. These complementary systems offer powerful experimental platforms for investigating the molecular determinants of spontaneous prion formation, strain selection and transmission barriers, providing insights into idiopathic prion pathogenesis and developing therapeutic interventions., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21 granted to Joaquín Castilla, PID2020-117465GB-I00 granted to Jesús R. Requena, and PID2021-1222010B-C22 granted to Enric Vidal, funded by MCIN/AEI/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027) granted to Joaquín Castilla, Hasier Eraña and Enric Vidal. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to Joaquín Castilla, also funded by Ministerio de Ciencia e Innovación/AEI/10.13039/501100011033. Transgenic Facility of IBSAL-University of Salamanca, directed by Manuel A. Sánchez‑Martín, is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. Eva Fernández-Muñoz received funding from Fundación Tatiana Pérez de Guzmán el Bueno, grant BN661-FTPGB-2023. This work also received funding from the Creutzfeldt-Jakob Disease Foundation—2022. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Rapid generation of prion disease models using AAV-delivered PrP variants in knockout mice

  • San-Juan-Ansoleaga, Maitena
  • Fernández-Muñoz, Eva
  • Charco, Jorge M.
  • Vidal, Enric
  • Herrero-Martínez, Diego
  • Galarza-Ahumada, Josu
  • Sampedro-Torres-Quevedo, Cristina
  • Giler, Samanta
  • Geijo, Mariví
  • González-Aseguinolaza, Gloria
  • Eraña, Hasier
  • Castilla, Joaquín
The study of prion biology has traditionally relied on transgenic mouse models, which, while valuable, require significant time and resources to develop. Here, we present a rapid and flexible alternative using adeno-associated virus (AAV) vectors to express modified prion proteins in PrP-knockout (PrP-KO) mice. Through systematic evaluation of multiple AAV constructs, we optimized vector design by comparing different CNS-specific promoters and regulatory elements to generate prion disease models capable of faithfully propagating the inoculated prion strain. We identified an optimized AAV construct incorporating the human synapsin promoter, MVM enhancer, and WPRE posttranscriptional regulatory element encapsidated in the AAV9P31 serotype to drive neuron-specific expression of modified mouse PrP (W144Y epitope) and bank vole I109 PrP (W145Y epitope). Following intravenous administration, we achieved brain-wide expression at levels comparable to or even exceeding endogenous PrP in some regions. When challenged with mouse-adapted RML prions or human Gerstmann-Sträussler-Scheinker (GSS-A117V) disease-causing prions, AAV-PrP mice developed characteristic signs of prion disease with accelerated kinetics (58–106 days post-inoculation for RML; 105–112 dpi for GSS-A117V), displaying features typical of each strain. Serial transmission of AAV-generated RML prions to wild-type mice confirmed preservation of strain-specific properties (165 ± 4 dpi), validating the authenticity of prion propagation in this system. This approach provides a versatile platform for rapidly generating and studying prion variants in an authentic brain environment. By reducing model generation time from months to weeks, this system enables accelerated investigation of prion structure–function relationships, strain properties, and therapeutic strategies, with potential applications extending to other protein misfolding diseases., The present work was partially funded by four grants awarded by the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (Spanish Government): grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21, and PID2021-122201OB-C22, funded by MCIN/AEI/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF); and grant EFA031/01 NEURO-COOP, co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021-2027). Additional support was provided by the CJD Foundation (2024 grant). CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation (CEX2021-001136-S), funded by MCIN/AEI/10.13039/501100011033. Additionally, Eva Fernández-Muñoz received funding from Fundacion Tatiana Perez de Guzman el Bueno, PhD grant BN661-FTPGB-2023. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Cofactors facilitate bona fide prion misfolding in vitro but are not necessary for the infectivity of recombinant murine prions

  • Pérez-Castro, Miguel Ángel
  • Eraña, Hasier
  • Vidal, Enric
  • Charco, Jorge M.
  • Lorenzo, Nuria L.
  • Gonçalves-Anjo, Nuno
  • Galarza-Ahumada, Josu
  • Díaz-Domínguez, Carlos M.
  • Piñeiro, Patricia
  • González-Miranda, Ezequiel
  • Giler, Samanta
  • Telling, Glenn
  • Sánchez-Martín, Manuel A.
  • Garrido, Joseba
  • Geijo, Mariví
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion diseases, particularly sporadic cases, pose a challenge due to their complex nature and heterogeneity. The underlying mechanism of the spontaneous conversion from PrPC to PrPSc, the hallmark of prion diseases, remains elusive. To shed light on this process and the involvement of cofactors, we have developed an in vitro system that faithfully mimics spontaneous prion misfolding using minimal components. By employing this PMSA methodology and introducing an isoleucine residue at position 108 in mouse PrP, we successfully generated recombinant murine prion strains with distinct biochemical and biological properties. Our study aimed to explore the influence of a polyanionic cofactor in modulating strain selection and infectivity in de novo-generated synthetic prions. These results not only validate PMSA as a robust method for generating diverse bona fide recombinant prions but also emphasize the significance of cofactors in shaping specific prion conformers capable of crossing species barriers. Interestingly, once these conformers are established, our findings suggest that cofactors are not necessary for their infectivity. This research provides valuable insights into the propagation and maintenance of the pathobiological features of cross-species transmissible recombinant murine prion and highlights the intricate interplay between cofactors and prion strain characteristics., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21 granted to J.C., PID2021-1222010B-C22 granted to E.V., and PID2020-117465GB-I00 granted to J.R.R., funded by MCIN/ AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021-2027) granted to J.C. and H.E. Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, granted to J.C. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to J.C., also funded by Ministerio de Ciencia e Innovación/AEI /10.13039/501100011033. Transgenic Facility, directed by M.A.S.-M., is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Effect of primary structural variation on cervid prion protein in flexibility, stability, and spontaneous misfolding propensity

  • Díaz-Domínguez, Carlos M.
  • Eraña, Hasier
  • Peccati, Francesca
  • Vidal, Enric
  • Charco, Jorge M.
  • Sampedro-Torres-Quevedo, Cristina
  • Pérez-Castro, Miguel A.
  • Lorenzo, Nuria L.
  • Giler, Samanta
  • Telling, Glenn C.
  • Geijo, Mariví
  • Requena, Jesús R.
  • Jiménez-Osés, Gonzalo
  • Castilla, Joaquín
Protein misfolding is central to numerous neurodegenerative disorders, collectively known as proteinopathies, which include Alzheimer's disease, Parkinson's disease, and prion diseases, among others. In many cases, specific polymorphisms of the proteins associated with these diseases influence their misfolding. However, the precise ways in which these polymorphisms affect protein integrity and how they contribute to misfolding propensity remain unclear. In the case of prion diseases, they are caused by prions or PrPSc, the misfolded isoforms of the cellular prion protein (PrPC). Chronic Wasting Disease (CWD) is a prion disease that affects cervids and can exhibit lymphotropic properties, making it the most widespread proteinopathy. For that reason, cervid PrPs and their polymorphisms have been extensively studied. To better understand the role of these polymorphisms, we analyzed 45 cervid PrP variants to assess their effects on flexibility, stability, and spontaneous misfolding propensity. The cervid variants were expressed as recombinant PrP in E. coli and were analyzed for thermal stability using circular dichroism. Additionally, the rec-PrPs served as substrates for Protein Misfolding Shaking Amplification (PMSA), enabling assessment of each variant's spontaneous misfolding propensity. This process led to the formation of bona fide prions, as confirmed by inoculation of one of the resulting conformers into transgenic mice expressing bank vole PrP. In parallel, molecular dynamics simulations were conducted to analyze the structural flexibility of the variants. While differences in protein flexibility were observed, no correlation was detected among flexibility, thermal stability, and the observed variable spontaneous misfolding propensity, suggesting that these properties are independent parameters., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21, PID2021-1222010B-C22, and PID2020-117465GB-I00, funded by MCIN/AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). Also funded by MCIN/AEI /10.13039/501100011033, F.P. and G.J.O. were provided with the grants RYC2022-036457-I and PID2021-125946OB-I00, respectively. EFA031/01 NEURO-COOP, which is co-funded at 65 % by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021-2027). Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, as part of a grant from the European Joint Program for Neurodegenerative Research (JPND) JPND-2021-650-130. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S, also funded by MCIN/AEI /10.13039/501100011033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Conservation of strain properties of bank vole-adapted chronic wasting disease in the absence of glycosylation and membrane anchoring

  • Vidal, Enric
  • Eraña, Hasier
  • Charco, Jorge M.
  • Lorenzo, Nuria L.
  • Giler, Samanta
  • Ordóñez, Montserrat
  • Fernández-Muñoz, Eva
  • San-Juan-Ansoleaga, Maitena
  • Telling, Glenn C.
  • Sánchez-Martín, Manuel A.
  • Geijo, Mariví
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion disease phenotypes (prion strains) are primarily determined by the specific misfolded conformation of the cellular prion protein (PrPC). However, post-translational modifications, including glycosyl phosphatidyl inositol (GPI) membrane anchoring and glycosylation, may influence strain characteristics. We investigated whether these modifications are essential for maintaining the unique properties of bank vole-adapted Chronic Wasting Disease (CWD-vole), the fastest known prion strain. Using a novel transgenic mouse model expressing I109 bank vole PrPC lacking the GPI anchor and largely devoid of glycans, we performed serial passages of CWD-vole prions. Despite elongated initial incubation periods, the strain maintained 100 % attack rate through three passages. Although the pathological phenotype showed characteristic GPI-less features, including abundant extracellular plaque formation, three subsequent serial passages in fully glycosylated and GPI-anchored bank vole I109 PrPC expressing transgenic mice TgVole (1×) demonstrated that the strain's distinctive rapid propagation properties were preserved. These findings suggest that neither GPI anchoring nor glycosylation are essential for maintaining CWD-vole strain properties, supporting the concept that strain characteristics are primarily encoded in the protein's misfolded structure., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21 and PID2021-1222010B-C22, and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65 % by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027). Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024 as member of a JPND grant JPND-2021-650-130. Additionally, CICbioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S, also funded by MCIN/AEI/10.13039/501100011033. Transgenic Facility, directed by M.A. S-M, is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Architecture of the ESCPE-1 membrane coat

  • López-Robles, Carlos
  • Scaramuzza, Stefano
  • Astorga-Simón, Elsa N.
  • Ishida, Morié
  • Williamson, Chad D.
  • Baños-Mateos, Soledad
  • Gil-Cartón, David
  • Romero-Durana, Miguel
  • Vidaurrazaga, Ander
  • Fernández-Recio, Juan
  • Rojas, Adriana L.
  • Bonifacino, Juan S.
  • Castaño-Díez, Daniel
  • Hierro, Aitor
Recycling of membrane proteins enables the reuse of receptors, ion channels and transporters. A key component of the recycling machinery is the endosomal sorting complex for promoting exit 1 (ESCPE-1), which rescues transmembrane proteins from the endolysosomal pathway for transport to the trans-Golgi network and the plasma membrane. This rescue entails the formation of recycling tubules through ESCPE-1 recruitment, cargo capture, coat assembly and membrane sculpting by mechanisms that remain largely unknown. Herein, we show that ESCPE-1 has a single-layer coat organization and suggest how synergistic interactions between ESCPE-1 protomers, phosphoinositides and cargo molecules result in a global arrangement of amphipathic helices to drive tubule formation. Our results thus define a key process of tubule-based endosomal sorting., This work was funded by MCIN/AEI/10.13039/501100011033 (PID2020- 119132GB-I00, CEX2021-001136-S) (to A.H.), the Intramural Program of NICHD, NIH (ZIA HD001607 to J.S.B.), the Swiss National Science Foundation grant 205321 179041 (to D.C.-D.), the Human Frontiers Science Program grant RGP0017/2020 (to D.C.-D.) and the PID2021- 127309NB-I00 funded by AEI/10.13039/501100011033/ FEDER, UE (to D.C.-D.). This study made use of the Diamond Light Source proposal MX20113, ALBA synchrotron beamline BL13-XALOC, the cryo-EM facilities at the UK Electron Bio-Imaging Centre, proposals EM17171- 6 and EM17171, and the Midlands Regional Cryo-EM Facility at the Leicester Institute of Structural and Chemical Biology (LISCB). We thank C. Savva (LISCB, University of Leicester) for his help in cryo-EM data collection. With funding from the Spanish government through the Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001136-S)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Physical Virology in Spain

  • Reguera, David
  • Pablo, Pedro J. de
  • Abrescia, Nicola G. A.
  • Mateu, Mauricio G.
  • Hernández-Rojas, Javier
  • Castón, José R.
  • San Martín, Carmen
Virus particles consist of a protein coat that protects their genetic material and delivers it to the host cell for self-replication. Understanding the interplay between virus structure and function is a requirement for understanding critical processes in the infectious cycle such as entry, uncoating, genome metabolism, capsid assembly, maturation, and propagation. Together with well-established techniques in cell and molecular biology, physical virology has emerged as a rapidly developing field, providing detailed, novel information on the basic principles of virus assembly, disassembly, and dynamics. The Spanish research community contains a good number of groups that apply their knowledge on biology, physics, or chemistry to the study of viruses. Some of these groups got together in 2010 under the umbrella of the Spanish Interdisciplinary Network on Virus Biophysics (BioFiViNet). Thirteen years later, the network remains a fertile ground for interdisciplinary collaborations geared to reveal new aspects on the physical properties of virus particles, their role in regulating the infectious cycle, and their exploitation for the development of virus-based nanotechnology tools. Here, we highlight some achievements of Spanish groups in the field of physical virology., The authors acknowledge funding by grants from the Spanish Ministry of Economy, Industry and Competitiveness (FIS2017-89549-R, MDM-2014-0377, and FIS2017-90701-REDT); the Human Frontiers Science Program (HFSPO RGP0012/2018); the Spanish State Research Agency (AEI/10.13039/501100011033); the European Regional Development Fund (PID2019-104098GB-I00, PID2019-105225GB-I00, RTI2018-096635-B-I00, PID2021-126130OB-100, PID2021-126570NB-I00, PID2021-126608OB-I00, and PID2021-126973OB-I00); the Spanish State Research Agency (CEX2021-00154-S, CEX2021-001136-S, PID2020-113287RB-I00, PID2022-136456NB-I00, RED2022-134221-T, and RED2022-134654-T); CSIC (2023AEP082 and 202120E47, LifeHub); and the Comunidad Autónoma de Madrid (P2018/NMT-4389)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-00154-S) and (CEX2021-001136-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

  • Goikoetxea-Usandizaga, Naroa
  • Bravo, Miren
  • Egia-Mendikute, Leire
  • Abecia, Leticia
  • Serrano-Maciá, Marina
  • Urdinguio, Rocío G.
  • Clos-García, Marc
  • Rodríguez-Agudo, Rubén
  • Araujo-Legido, Raquel
  • López-Bermudo, Lucía
  • Delgado, Teresa C.
  • Lachiondo-Ortega, Sofía
  • González-Recio, Irene
  • Gil-Pitarch, Clàudia
  • Peña-Cearra, Ainize
  • Simón, Jorge
  • Benedé-Ubieto, Raquel
  • Ariño, Silvia
  • Herranz, Jose M.
  • Azkargorta, Mikel
  • Salazar-Bermeo, Julio
  • Martí, Nuria
  • Varela-Rey, Marta
  • Falcón-Pérez, Juan M.
  • Lorenzo, Óscar
  • Nogueiras, Rubén
  • Elortza, Félix
  • Nevzorova, Yulia
  • Cubero, Francisco J.
  • Saura, Domingo
  • Martínez-Cruz, Luis Alfonso
  • Sabio, Guadalupe
  • Palazón, Asís
  • Palazón, Asís
  • Sancho-Bru, Pau
  • Elguezabal, Natalia
  • Fraga, Mario F.
  • Ávila, Matías A.
  • Bataller, Ramón
  • Marín, José J. G.
  • Martín, Franz
  • Martínez-Chantar, María Luz
Background and Aims: Alcohol-associated liver disease (ALD) accounts for 70% of liver-related deaths in Europe, with no effective approved therapies. Although mitochondrial dysfunction is one of the earliest manifestations of alcohol-induced injury, restoring mitochondrial activity remains a problematic strategy due to oxidative stress. Here, we identify methylation-controlled J protein (MCJ) as a mediator for ALD progression and hypothesize that targeting MCJ may help in recovering mitochondrial fitness without collateral oxidative damage. Approach and Results: C57BL/6 mice [wild-type (Wt)] Mcj knockout and Mcj liver-specific silencing (MCJ-LSS) underwent the NIAAA dietary protocol (Lieber-DeCarli diet containing 5% (vol/vol) ethanol for 10 days, plus a single binge ethanol feeding at day 11). To evaluate the impact of a restored mitochondrial activity in ALD, the liver, gut, and pancreas were characterized, focusing on lipid metabolism, glucose homeostasis, intestinal permeability, and microbiota composition. MCJ, a protein acting as an endogenous negative regulator of mitochondrial respiration, is downregulated in the early stages of ALD and increases with the severity of the disease. Whole-body deficiency of MCJ is detrimental during ALD because it exacerbates the systemic effects of alcohol abuse through altered intestinal permeability, increased endotoxemia, and dysregulation of pancreatic function, which overall worsens liver injury. On the other hand, liver-specific Mcj silencing prevents main ALD hallmarks, that is, mitochondrial dysfunction, steatosis, inflammation, and oxidative stress, as it restores the NAD+/NADH ratio and SIRT1 function, hence preventing de novo lipogenesis and improving lipid oxidation. Conclusions: Improving mitochondrial respiration by liver-specific Mcj silencing might become a novel therapeutic approach for treating ALD., This work was supported by grants from Ministerio de Ciencia e Innovación, Programa Retos-Colaboración RTC2019-007125-1 (for Jorge Simon and Maria Luz Martinez-Chantar); Ministerio de Economía, Industria y Competitividad, Retos a la Sociedad AGL2017- 86927R (for F.M.); Instituto de Salud Carlos III, Proyectos de Investigación en Salud DTS20/00138 and DTS21/00094 (for Jorge Simon and Maria Luz Martinez-Chantar, and Asis Palazon. respectively); Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias co-founded by European Regional Development Fund/European Social Fund, “Investing in your future” PI19/00819, “Una manera de hacer Europa” FIS PI20/00765, and PI21/01067 (for Jose J. G. Marin., Pau Sancho-Bru,. and Mario F. Fraga respectively); Departamento de Industria del Gobierno Vasco (for Maria Luz Martinez-Chantar); Asturias Government (PCTI) co-funding 2018-2023/ FEDER IDI/2021/000077 (for Mario F. Fraga.); Ministerio de Ciencia, Innovación y Universidades MICINN: PID2020-117116RB-I00, CEX2021-001136-S PID2020-117941RB-I00, PID2020-11827RB-I00 and PID2019-107956RA-100 integrado en el Plan Estatal de Investigación Científica y Técnica y Innovación, cofinanciado con Fondos FEDER (for Maria Luz Martinez- Chantar, Francisco J Cubero., Yulia A Nevzorova and Asis Palazon); Ayudas Ramón y Cajal de la Agencia Estatal de Investigación RY2013-13666 and RYC2018- 024183-I (for Leticia Abecia and Asis Palazon); European Research Council Starting Grant 804236 NEXTGEN- IO (for Asis Palazon); The German Research Foundation SFB/TRR57/P04, SFB1382-403224013/ A02 and DFG NE 2128/2-1 (for Francisco J Cubero and Yulia A Nevzorova); National Institute of Health (NIH)/National Institute of Alcohol Abuse and Alcoholism (NIAAA) 1U01AA026972-01 (For Pau Sancho-Bru); Junta de Castilla y León SA074P20 (for Jose J. G. Marin); Junta de Andalucía, Grupo PAIDI BIO311 (for Franz Martin); CIBERER Acciones Cooperativas y Complementarias Intramurales ACCI20-35 (for Mario F. Fraga); Ministerio de Educación, Cultura y Deporte FPU17/04992 (for Silvia Ariño); Fundació Marato TV3 201916-31 (for Jose J. G. Marin.); Ainize Pena-Cearra is a fellow of the University of the Basque Country (UPV/ EHU); BIOEF (Basque Foundation for Innovation and Health Research); Asociación Española contra el Cáncer (Maria Luz Martinez-Chantar and Teresa C. Delgado.); Fundación Científica de la Asociación Española Contra el Cáncer (AECC Scientific Foundation) Rare Tumor Calls 2017 (for Maria Luz Martinez-Chantar); La Caixa Foundation Program (for Maria Luz Martinez-Chantar); Proyecto Desarrollo Tecnologico CIBERehd (for Maria Luz Martinez-Chantar); Ciberehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

  • Rodríguez-Agudo, Rubén
  • González-Recio, Irene
  • Serrano-Maciá, Marina
  • Bravo, Miren
  • Petrov, Petar D.
  • Blaya, Delia
  • Herranz, José María
  • Mercado-Gómez, María
  • Rejano-Gordillo, Claudia María
  • Lachiondo-Ortega, Sofía
  • Gil-Pitarch, Clàudia
  • Azkargorta, Mikel
  • Liempd, Sebastiaan Martijn van
  • Martínez-Cruz, Luis Alfonso
  • Simão, A. L.
  • Elortza, Félix
  • Martín, César
  • Nevzorova, Yulia A.
  • Cubero, Francisco Javier
  • Delgado, Teresa C.
  • Argemi, Josepmaria
  • Bataller, Ramón
  • Schoonjans, Kristina
  • Banales, Jesús M.
  • Castro, Rui E.
  • Sancho-Bru, Pau
  • Ávila, Matías A.
  • Julve, Josep
  • Jover, Ramiro
  • Mabe, Jon
  • Simón, Jorge
  • Goikoetxea-Usandizaga, Naroa
  • Martínez-Chantar, María Luz
© 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., [Background & Aims] Current therapies for the treatment of alcohol-related liver disease (ALD) have proven largely ineffective. Patients relapse and the disease progresses even after liver transplantation. Altered epigenetic mechanisms are characteristic of alcohol metabolism given excessive acetate and NAD depletion and play an important role in liver injury. In this regard, novel therapeutic approaches based on epigenetic modulators are increasingly proposed. MicroRNAs, epigenetic modulators acting at the post-transcriptional level, appear to be promising new targets for the treatment of ALD., [Methods] MiR-873-5p levels were measured in 23 liver tissue from Patients with ALD, and GNMT levels during ALD were confirmed using expression databases (transcriptome n = 62, proteome n = 68). High-resolution proteomics and metabolomics in mice following the Gao-binge model were used to investigate miR-873-5p expression in ALD. Hepatocytes exposed to 50 mM alcohol for 12 h were used to study toxicity. The effect of anti-miR-873-5p in the treatment outcomes of ALD was investigated., [Results] The analysis of human and preclinical ALD samples revealed increased expression of miR-873-5p in the liver. Interestingly, there was an inverse correlation with NNMT, suggesting a novel mechanism for NAD depletion and aberrant acetylation during ALD progression. High-resolution proteomics and metabolomics identified miR-873-5p as a key regulator of NAD metabolism and SIRT1 deacetylase activity. Anti-miR-873-5p reduced NNMT activity, fuelled the NAD salvage pathway, restored the acetylome, and modulated the levels of NF-κB and FXR, two known SIRT1 substrates, thereby protecting the liver from apoptotic and inflammatory processes, and improving bile acid homeostasis., [Conclusions] These data indicate that targeting miR-873-5p, a repressor of GNMT previously associated with NAFLD and acetaminophen-induced liver failure. is a novel and attractive approach to treating alcohol-induced hepatoxicity., [Impact and implications] The role of miR-873-5p has not been explicitly examined in the progression of ALD, a pathology with no therapeutic options. In this study, inhibiting miR-873-5p exerted hepatoprotective effects against ALD through rescued SIRT1 activity and consequently restored bile acid homeostasis and attenuated the inflammatory response. Targeting hepatic miR-873-5p may represent a novel therapeutic approach for the treatment of ALD., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001136-S)., This work was supported by grants from Ministerio de Ciência, Innovación y Universidades MICINN: PID2020-117116RB-I00 CEX2021-001136-S integrado en el Plan Estatal de Investigación Científica y Técnica e Innovación, cofinanciado con Fondos FEDER (to MLM-C); Ministerio de Ciência e Innovación, Programa Retos-Colaboración RTC2019-007125-1 (to MLM-C); Instituto de Salud Carlos III, Proyectos Investigación en Salud DTS20/00138 (to MLM-C); La Caixa Scientific Foundation (HR17-00601) (for REC, MLM-C and JMB); La Caixa Consortium (to JMB, REC, KS and MLM-C); Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias co-founded by the European Union, PI20/00690, PI20/00765, PI20/01663 and PI21/00922 (to RJ, PS-B, JA and JMB respectively); Miguel Servet Programme CPII19/00008 (to JMB); AMMF-The Cholangiocarcinoma Charity (EU/2019/AMMFt/001) (to JMB); PSC Partners US and PSC Supports UK 06119JB (to JMB); European Union’s Horizon 2020 Research and Innovation Program, 825510 (for JMB) Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III (Madrid, Spain) grant PI21/00770 (for JJ), Fundação para a Ciência e a Tecnologia (grants PTDC/MED-PAT/31882/2017 and EXPL/MED-OUT/1317/2021 to REC and ALS)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SUMOylation modulates eIF5A activities in both yeast and pancreatic ductal adenocarcinoma cells

  • Seoane, Rocío
  • Lama-Díaz, Tomás
  • Romero, Antonia María
  • El Motiam, Ahmed
  • Martínez-Férriz, Arantxa
  • Vidal, Santiago
  • Bouzaher, Yanis H.
  • Blanquer, María
  • Tolosa, Rocío M.
  • Castillo Mewa, Juan
  • Álvarez-Rodríguez, Manuel
  • García-Sastre, Adolfo
  • Xirodimas, Dimitris
  • Sutherland, James D.
  • Barrio, Rosa
  • Alepuz, Paula
  • Blanco, Miguel G.
  • Farràs, Rosa
  • Rivas, Carmen
The eukaryotic translation initiation protein eIF5A is a highly conserved and essential factor that plays a critical role in different physiological and pathological processes including stress response and cancer. Different proteomic studies suggest that eIF5A may be a small ubiquitin-like modifier (SUMO) substrate, but whether eIF5A is indeed SUMOylated and how relevant is this modification for eIF5A activities are still unknown., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. Funding at the laboratory of CR is provided by Ministry of Science, Innovation and Universities and FEDER (BFU-2017-88880-P), (PID2021-126510NB-I00), and Xunta de Galicia (ED431G 2023/10). RS, SV and TLD are predoctoral fellows funded by Xunta de Galicia-Consellería de Cultura, Educación y Ordenación Universitaria (ED481A-2020/160, ED481A-2018/110, and ED481A-2018/042, respectively). AMR is a postdoctoral funded by Generalitat Valenciana (CIAPOS2021/117). MB is a predoctoral fellow funded by Banco Santander and University of Santiago de Compostela. RMT is a predoctoral fellow funded by Instituto de Investigación Sanitaria de Santiago de Compostela. The Blanco lab is supported by MCIN/AEI/https://doi.org/10.13039/501100011033 [PID2020-115472 GB-I00] and Xunta de Galicia/ FEDER ‘Una manera de hacer Europa’ [ED431C 2019/013]. RF lab is supported by Fondo de Investigación Sanitaria, ISCIII (PI20-00194). PA lab is supported by MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2020-120066RB-I00) and by GVA CIAICO/2022/237. AMF is a predoctoral fellow funded by Asociación Española Contra el Cáncer (AECC APRO 2018). RB and JDS thank MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2020-114178 GB-I00, CEX2021-001136-S). CR, RF and RB acknowledge SAF2017-90900-REDT support (UBIRed Program, Spain) and COST Action ProteoCure CA20113., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The microbiota metabolite, phloroglucinol, confers long-term protection against inflammation

  • Castelo, Janire
  • Araujo-Aris, Sarai
  • Barriales, Diego
  • Tanner Pasco, Samuel
  • Seoane, Iratxe
  • Peña-Cearra, Ainize
  • Palacios, Ainhoa
  • Simó, Carolina
  • García-Cañas, Virginia
  • Khamwong, Muthita
  • Martín-Ruiz, Itziar
  • Gonzalez-Lopez, Monika
  • Bárcena, Laura
  • Martín Rodríguez, José Ezequiel
  • Lavín, José Luís
  • Gutiez, Naiara
  • Marcos-Fernández, Raquel
  • Atondo, Estíbaliz
  • Cobela, Arantza
  • Plaza-Vinuesa, Laura
  • Plata, Adrián
  • Santos-Fernandez, Eneko
  • Fernandez-Tejada, Alberto
  • Villarán, Mari Carmen
  • Mancheño, Jose M.
  • Maria Flores, Juana
  • María Aransay, Ana
  • Pellón, Aize
  • De Las Rivas, Blanca
  • Muñoz, Rosario
  • Margolles Barros, Abelardo
  • Ruas-Madiedo, Patricia
  • Victoria Selma, Maria
  • Gomez de Agüero, Mercedes
  • Abecia, Leticia
  • Anguita, Juan
  • Rodríguez, Héctor
Phloroglucinol is a key byproduct of gut microbial metabolism that has been widely used as a treatment for irritable bowel syndrome. Here, we demonstrate that phloroglucinol tempers macrophage responses to pro-inflammatory pathogens and stimuli. In vivo, phloroglucinol administration decreases gut and extraintestinal inflammation in murine models of inflammatory bowel disease and systemic infection. The metabolite induces modest modifications in the microbiota. However, the presence of an active microbiota is required to preserve its anti-inflammatory activity. Remarkably, the protective effect of phloroglucinol lasts partially at least 6 months. Single-cell transcriptomic analysis of bone marrow progenitors demonstrates the capacity of the metabolite to induce long-lasting innate immune training in hematopoietic lineages, at least partially through the participation of the receptor and transcription factor, aryl hydrocarbon receptor (AhR). Phloroglucinol induces alterations in metabolic and epigenetic pathways that are most prevalent in upstream progenitors as hallmarks of central trained immunity. These data identify phloroglucinol as a dietary-derived compound capable of inducing central trained immunity and modulating the response of the host to inflammatory insults., This work was supported by MCIN/AEI/10.13039/501100011033(PID2021-124328OB-100 to JA, AGL2017-86757-R and RYC-2013-13666 to LA, SAF2015-73549-JIN to HR, PID2020-117911RB-100 to AFT). MGA is funded by the DeutscheForschungsgemeinschaft (DFG, German researchFoundation) – SFB 1583/1 [Project number: 492620490] andSPP 2330 [Project number: 465341196]. Supported in part byFundación Jesús de Gangoiti and by fellowships from Getteccu(Geteccu-MSD to HR and LA, and Geteccu-FreseniusKabi to JA).CIC bioGUNE is the recipient of a Severo Ochoa Centro deExcelencia award [CEX2021-001136-S].JC was partly supported18 J. CASTELO ET AL. by a FEMS Research and Training Grant [1816] and an EMBOScientific Exchange Grant [9792]. APa and IS were supported bya predoctoral fellowship from the Basque Government. APe wassupported by a postdoctoral fellowship from the BasqueGovernment. DB [BES-2016-078437], SAA [PRE-2019-091720],APl [PRE2018-085772] and ESF [PRE2022-104669] were recipi-ents of MCIU FPI fellowships from MCIN/AEI/10.13039/501100011033. APC was a recipient of a fellowship from theUniversity of the Basque Country. NG held a predoctoral grantfrom the Scientific Foundation of the Spanish AssociationAgainst Cancer in Biscay [PRDVZ222452GUTI]. We thank theBasque Department of Industry, Tourism and Trade (Etortek andElkartek programs) and the Innovation Technology Departmentof the Bizkaia Province. This project has received funding fromthe European Union’s Horizon 2020 research and innovationprogramme under the Marie Skłodowska-Curie grant agreementNº 860325 to STP and JA., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The lipopolysaccharide-TLR4 axis regulates hepatic glutaminase 1 expression promoting liver ammonia build-up as steatotic liver disease progresses to steatohepatitis

  • Mercado-Gómez, Maria
  • Goikoetxea-Usandizaga, Naroa
  • Kerbert, Annarein J.C.
  • Uraga Gracianteparaluceta, Leire
  • Serrano-Maciá, Marina
  • Lachiondo-Ortega, Sofía
  • Rodríguez-Agudo, Rubén
  • Gil-Pitarch, Clàudia
  • Simón, Jorge
  • González-Recio, Irene
  • Fondevila, Marcos F.
  • Santamarina-Ojeda, Pablo
  • Fraga, Mario F.
  • Nogueiras, Rubén
  • Heras, Javier de las
  • Jalan, Rajiv
  • Martínez-Chantar, María Luz
  • Delgado, Teresa C.
[Introduction]: Ammonia is a pathogenic factor implicated in the progression of metabolic-associated steatotic liver disease (MASLD). The contribution of the glutaminase 1 (GLS) isoform, an enzyme converting glutamine to glutamate and ammonia, to hepatic ammonia build-up and the mechanisms underlying its upregulation in metabolic-associated steatohepatitis (MASH) remain elusive., [Methods]: Multiplex transcriptomics and targeted metabolomics analysis of liver biopsies in dietary mouse models representing the whole spectra of MASLD were carried out to characterize the relevance of hepatic GLS during disease pathological progression. In addition, the acute effect of liver-specific GLS inhibition in hepatic ammonia content was evaluated in cultured hepatocytes and in in vivo mouse models of diet-induced MASLD. Finally, the regulatory mechanisms of hepatic GLS overexpression related to the lipopolysaccharide (LPS)/Toll-like receptor 4 (TLR4) axis were explored in the context of MASH., [Results]: In mouse models of diet-induced MASLD, we found that augmented liver GLS expression is closely associated with the build-up of hepatic ammonia as the disease progresses from steatosis to steatohepatitis. Importantly, the acute silencing/pharmacological inhibition of GLS diminishes the ammonia burden in cultured primary mouse hepatocytes undergoing dedifferentiation, in steatotic hepatocytes, and in a mouse model of diet-induced steatohepatitis, irrespective of changes in ureagenesis and gut permeability. Under these conditions, GLS upregulation in the liver correlates positively with the hepatic expression of TLR4 that recognizes LPS. In agreement, the pharmacological inhibition of TLR4 reduces GLS and hepatic ammonia content in LPS-stimulated mouse hepatocytes and hyperammonemia animal models of endotoxemia., [Conclusions]: Overall, our results suggest that the LPS/TLR4 axis regulates hepatic GLS expression promoting liver ammonia build-up as steatotic liver disease progresses to steatohepatitis., TC Delgado is funded by “Ayuda RYC2020-029316-I financiada por MCIN/AEI/10.13039/501100011033 y por El FSE invierte en tu future”. This work was supported by the Gilead Sciences Research Scholars Program in Global Liver (to TCD), Nanostring® grant (to TCD); grant from Ministerio de Ciencia, Innovación y Universidades (MICINN: PID2022-139395OB-100 integrado en el Plan Estatal de Investigación Científica y Técnica e Innovación, con Fondos FEDER); grants from Ministerio de Ciencia, Innovación y Universidades MICINN: PID2020-117116RB-I00 CEX2021-001136-S integrado en el Plan Estatal de Investigación Científica y Técnica e Innovación, cofinanciado con Fondos FEDER for (MLM-C); Project funded by CIBEREHD; La Caixa Scientific Foundation (HR17-00601) (for MLM-C); ERA-Net E-Rare EJP RD Joint Translational Call for Rare Diseases FIGHT-CNNM2 (EJPRD19-040), and from Instituto Carlos III, Spain (for MLM-C, JH); the Basque Department of Education (IT1739-22) (for JH). JH and TCD are members of the European Reference Network for Rare Hereditary Metabolic Disorders (MetabERN) Project ID No. 739543., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001136-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Propionate and butyrate counteract renal damage and progression to chronic kidney disease

  • Corte-Iglesias, Viviana
  • Saiz, María L.
  • Andrade-Lopez, Ana Cristina
  • Salazar, Nuria
  • Bernet, Cristian Ruiz
  • Martín-Martín, Cristina
  • Martínez Borra, Jesús Martinez
  • Lozano, Juan-Jose
  • Aransay, Ana M.
  • Díaz-Corte, Carmen
  • López-Larrea, Carlos
  • Suárez-Álvarez, Beatriz
Short-chain fatty acids (SCFAs), mainly acetate, propionate and butyrate, are produced by gut microbiota through fermentation of complex carbohydrates that cannot be digested by the human host. They affect gut health and can contribute at the distal level to the pathophysiology of several diseases, including renal pathologies., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects PI20/00639, PI22/00738 and PI23/00567 co-funded by the European Union; Adquisición de equipamiento e Infraestructuras científico-técnicas (IFEQ21/00203) and RICORS2040 (RD21/0005/0017) funded by the European Union through NextGenerationEU, which finances the activities of the Mechanism for Recovery and Resilience (MRR)/RETC; and PCTI-Plan de Ciencia, Tecnología e Innovación 2021-2023 del Gobierno del Principado de Asturias/FEDER (Grant number IDI/2021/000032). CIC bioGUNE support was provided by the Department of Industry, Tourism and Trade of the Government of the Autonomous Community of the Basque Country (Emaitek and Elkartek Research Programs 2015-2023), the Innovation Technology Department of the Bizkaia County and MINECO for the Severo Ochoa Excellence Accreditation (CEX2021-001136-S). The Miguel Servet Program from ISCIII supported to B.S.-A. (grant number CP18/00106). C.R.B (BP21/044) received a Severo Ochoa Grant from the Programa de Ayudas ‘Severo Ochoa’ para la formación en investigación y docencia del Principado de Asturias, Gobierno del Principado de Asturias. M.L.S. was funded by FEDER-PCTI 2021-2023, Gobierno del Principado de Asturias (grant number IDI/2021/000032). N.S. was the recipient of ISPA postdoctoral Junior contract financed by Fundación para la Investigación Biosanitaria of Asturias (FINBA) and she received Grant RYC2021-033521-I, funded by MCIN/AEI/10.13039/501100011033 and by the European Union NextGeneration EU/PRTR programme. Editorial assistance, in the form of language editing and correction, was provided by XpertScientific Editing and Consulting Services and Philip Mason Translations and Revisions., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

pH-antenna residues trigger a large-scale conformational change in the large extracellular loop domain of the CD81 human receptor

  • Risueño, Cristina
  • Carbajo, Irene
  • Charro, D.
  • Abrescia, N. G.
  • Coluzza, Ivan
CD81 is a human receptor that clusters into microdomains to mediate cell signaling processes. Previous structural studies on the CD81 large-extracellular-loop domain (CD81LEL) proposed that its conformation (ranging from closed to open) may depend on environmental pH conditions. However, the precise mechanism governing CD81LEL plasticity has remained unconfirmed until now. Here, by combining molecular dynamics simulations and spectroscopic experiments on CD81LEL, we show that the mechanism underlying the dependence of the changes in pH to the opening of CD81LEL relates to the modulation of the solvation shell by “antenna” residues. The antenna residues are D139 and E188. Under acidic conditions, such residues generate a signal cascade propagating through the CD81LEL molecule changing the local solvation that, in turn, acts as an effector of the closed-to-open conformational transition. We further proved the key role of D139 and E188 by introducing mutations that switch off their sensitivity to pH. As expected, the mutations stabilize the closed conformation. This signal transduction mechanism might play a role in other cellular receptors that function along the endosomal pathway., We acknowledge the computer resources at Tirant and technical support provided by the Spanish Supercomputing Network (Grant No. BCV-2019-2-0007). We also acknowledge the support of the computing infrastructure of the i2BASQUE academic network. This research was supported by the Spanish Ministerio de Ciencia, Innovación y Universidades (Grant Nos. RTI2018-095700-B-I00 and PID2021-126130OB-I00 to N.G.A.A.) and by the CIC bioGUNE and CIC biomaGUNE (Grant No. CICBMG-PhD-2018-02296 to CRF). MCIN is also acknowledged for the Severo Ochoa Excellence Accreditation to the CIC bioGUNE (Grant No. CEX2021-001136-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001136-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Modulatory effects of CNNM4 on protein- l -isoaspartyl- O -methyltransferase repair function during alcohol-induced hepatic damage

  • González-Recio, Irene
  • Goikoetxea-Usandizaga, Naroa
  • Rejano-Gordillo, Claudia María
  • Conter, Carolina
  • Rodriguez-Agudo, Rubén
  • Serrano-Maciá, Marina
  • Zapata-Pavas, L. Estefanía
  • Close Peña-Sanfélix, Patricia
  • Azkargorta, Mikel
  • Elortza, Félix
  • Herranz, José Maria
  • Guillamon-Thiery, Álex
  • Guerra-Ruiz, Armando Raúl
  • Jover-Atienza, Ramiro
  • Galicia-García, Unai
  • Martín, César A.
  • Schaeper, Ute
  • Cardoso-Delgado, Teresa
  • Díaz-Moreno, Irene
  • Díaz-Quintana, Antonio
  • Buccella, Daniela
  • Nogueiras, Rubén A.
  • Argemi, Josepmaria
  • Ávila, Matías A.
  • Gratacós-Ginès, Jordi
  • Pose, Elisa
  • Bataller, Ramon A.
  • Crespo-García, Javier V.
  • Martínez-Cruz, Luís Alfonso
  • Martínez-Chantar, María Luz
Chemicals and CAS Registry Numbers alcohol dehydrogenase 9031-72-5 methyltransferase 9033-25-4 alcohol 64-17-5 magnesium 7439-95-4 Ethanol Magnesium, ALD, alcohol-associated liver disease; CNNM4, Cyclin M4; ER, endoplasmic reticulum; PCMT1, L-isoaspartate O-methyltransferase; SAMe, S-adenosylmethionine; WT, wild type Supplemental Digital Content is available, Background and Aims: Alcohol-associated liver disease (ALD) is a leading cause of liver-related mortality worldwide, with limited treatment options beyond abstinence and liver transplantation. Chronic alcohol consumption has been linked to magnesium (Mg2+) deficiency, which can influence liver disease progression. The mechanisms underlying Mg2+ homeostasis dysregulation in ALD remain elusive. This study aimed to investigate the role of the Mg2+ transporter Cyclin M4 (CNNM4) in ALD by analyzing its expression patterns in patients with ALD and preclinical animal models. Approach and Results: In this study, CNNM4 is upregulated in the liver of both patients with ALD and animal models. CNNM4 overexpression triggers Mg2+ homeostasis dysregulation, linked to ALD progression. We propose a novel therapeutic approach for ALD treatment using N-acetylgalactosamine silencing RNA technology to specifically modulate Cnnm4 expression in the liver, improving mitochondrial function and alleviating endoplasmic reticulum stress. Notably, silencing Cnnm4 restores protein isoaspartyl methyltransferase (PCMT1) activity, essential for repairing ethanol-induced protein damage. Enhancing mitochondrial activity through Cnnm4-dependent mechanisms increases S-adenosylmethionine levels, crucial for PCMT1 function, highlighting the interconnected roles of mitochondrial health and protein homeostasis in ALD treatment. Conclusions: These findings shed light on the dysregulation of Mg2+ homeostasis in ALD, providing a promising therapeutic approach targeting CNNM4. N-acetylgalactosamine siCnnm4 therapy boosts the repair processes of ethanol-damaged proteins through the upregulation of PCMT1 activity., The authors acknowledge Begoña Rodríguez Iruretagoyena for the technical support., This work was supported by grants from Ministerio de Ciencia, Innovación y Universidades MICINN: PID2023-146933OB-100 funded by MCIU /AEI /10.13039/501100011033 / FEDER, UE as part of Plan Estatal de Investigación Científica y Técnica e Innovación (to MLM-C); Grant CEX2021-001136-S funded by MCIN/AEI /10.13039/501100011033 (to MLM-C); Instituto de Salud Carlos III (ISCIII) through the project PMP22/00054 "Exploring the Feasibility of predictive and pharmacodynamics biomarkers of immunotherapy in solid tumors (Immune4ALL)" and co-founded by the European Union; CIBEREHD\Project funded by CIBEREHD; La Caixa Banking Foundation under the project code CI23-20155 (CaixaImpulse) (to MLM-C); La Caixa Banking Foundation and FCT (HR17-00601) (to MLM-C); Programa Ayudas a proyectos de investigación y desarrollo en salud del Departamento de Salud del Gobierno Vasco (2023333041) (to MLM-C); Diputación Foral de Bizkaia dentro del Programa Transferencia Tecnológica 2022 (6/12/TT/2022/00001), co-founded by FEDER (to MLM-C); Proyecto Elkartek, Subvencionado por el Gobierno Vasco (to MLM-C); PhD fellowship from MINECO (REF BES-2017-080435) (to Irene González-Recio); Spanish Ministerio de Ciencia e Innovación (MICINN), Grants No PID2019-109055RB-I00, BFU2016-77408-R and PID2022-141748OB-I00, to L.A.M.-C; and grants by ERANet E-Rare No EJPRD19-040, and by Instituto Carlos III, No G95229142 (to Luis Alfonso Martínez-Cruz); PI22/01853 from reactive to perspective medicine in NAFLD: Identification a novel signature for progression in early NAFLD, PMP21/00112 Dianas terapéuticas y biomarcadores para la medicina de precision en MAFLD (PreMed-MAFLD), PI18/01304 Immunomediatd Nonalcoholic SteaTohepatItis; prevalence and CharacTerization. INSTInCT study (to Javier Crespo and Paula Iruzubieta). Instituto de Salud Carlos III FIS PI22/00910 (to Elisa Pose). Río Hortega grant (to Jordi Gratacós-Ginès), ISCIII-Acción Estratégica en Salud (AES), 2021 Call; FEDER/Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación PID2021-126096NB-I00 and RED2018-102379-T; Xunta de Galicia 2021-CP085 and 2020-PG0157 (to Rubén Nogueiras); Ministerio de Ciencia, Innovación PID2021-126663NB-I00, European Regional Development Fund (FEDER), Andalusian Government (BIO-198 and P18-FR-3487, US/JUNTA/FEDER, UE), University of Seville (VI PPIT-US), and the Ramón Areces´ Foundation (to Irene Díaz-Moreno); Ministry of Science and Innovation, grant number PID2022-138572OB-C42 (to Cesar Martín); “Ayuda RYC2020-029316-I financiada por MCIN/AEI/10.13039/501100011033 y por EL FSE invierte en tu future” (to Teresa C. Delgado); Instituto Carlos III PI20/00690 (to Ramiro Jover), cofounded by the European Union., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metabolic dysfunction-associated steatotic liver disease alters brain function and behavior: Insights from liver-targeted siRNA therapy

  • Cardoso Delgado, Teresa de Jesús
  • Martín-Cuevas, Celia
  • Sánchez-Hidalgo, Ana C.
  • Gil-Gómez, Antonio
  • Rejano-Gordillo, Claudia María
  • Landa, Jon
  • Gallego-Durán, Rocío
  • Goikoetxea-Usandizaga, Naroa
  • González-Recio, Irene
  • Gil-Pitarch, Clàudia
  • Zapata-Pavas, L. Estefanía
  • Barrenechea-Barrenechea, Jon Ander
  • Conter, Carolina
  • Martínez-Cruz, Luis Alfonso
  • Ramos Herrero, Víctor
  • Nogueiras, Rubén
  • Azkargorta, Mikel
  • Elortza, Félix
  • Moncho-Amor, Verónica
  • Crespo, Javier
  • Matheu, Ander
  • Romero-Gómez, Manuel
  • Crespo-Facorro, Benedicto
  • Martínez-Chantar, María Luz
[Data and materials availability:] The mass spectrometry proteomics data have been deposited in the ProteomeXchange Consortium via the PRIDE [1] partner repository with the dataset identifier PXD063321 (www.ebi.ac.uk/pride/archive/projects/PXD063321). All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials., Metabolic dysfunction–associated steatotic liver disease (MASLD), a liver-centric condition, is associated with cognitive impairment and sensorimotor alterations. However, it remains unclear whether MASLD is sufficient to drive central nervous system deficits. Here, using diet-induced mouse models, we showed that MASLD was associated with alterations in social memory, sensorimotor processing, and hippocampal function, including decreased parvalbumin-positive interneurons, reduced dendritic spine density, and diminished dentate gyrus neurogenesis and neuronal differentiation. Then, we selectively modulated liver metabolism through N-acetylgalactosamine small interfering RNA (siRNA) therapy against Cyclin M4 (CNNM4), a magnesium transporter dysregulated in MASLD. Liver-specific intervention with siRNA-Cnnm4 reversed impaired social memory and sensorimotor processing in association with recovery of hippocampal synaptogenesis and mitochondrial function pathways, alongside activation of neurogenesis-associated transcriptional programs. Our findings demonstrate that liver pathology is sufficient to drive neurobehavioral and hippocampal dysfunction in MASLD. Hepatic-specific intervention restores brain function, strongly supporting the existence of a causal and therapeutically targetable liver-brain axis for MASLD-associated neurological complications., This work was supported by grants from Ministerio de Ciencia, Innovación y Universidades MICINN: CEX2021-001136-S (to M.L.M.-C.) and MICINN: PID2022-139395OB-100 (to M.L.M.-C.); integrado en el Plan Estatal de Investigación Científica y Técnica e Innovación, cofinanciado con Fondos FEDER; and Project funded by CIBEREHD; 2018 BBVA Foundation Grants for Scientific Research Teams- UMBRELLA (to M.L.M.-C., M.R.G., and B.C.-F.). T.C.D. is funded by “Ayuda RYC2020-029316-I financiada por MCIN/AEI/10.13039/501100011033 y por El FSE invierte en tu futuro.” This work was supported by grants from Ministerio de Ciencia, Innovación y Universidades MICINN: PID2020-117116OB-I00 (to T.C.D.). C.M.-C. was supported by CIBERSAM (G26) and the Instituto de Salud Carlos III (AC23_2/00034). A.C.S.H. received funding from CIBERSAM (G26) and the Consejería de Salud y Familias (RH-0063). V.D.R.H. was supported by the Agencia Estatal de Investigación (PID2019-109405R and PI-0014-2022). L.E.Z.-P. was supported by a PhD fellowship from the Provincial Section of Bizkaia from the Scientific Foundation of the Spanish Association Against Cancer PRDVZ233980ZAPA. C.M.R.G. was supported by Ayuda Juan de la Cierva JDC2023-052761-I from the MCIN/AEI/10.13039/501100011033–Unión Europea NextGenerationEU/PRTR. V.M.-A. was supported by the Miguel Servet contract (CP23/00111) from the ISCIII. This project has also received funding from the European Horizon’s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 (agreement no. 101095679), Spanish Instituto de Salud Carlos III-FEDER Grant (FIS-PI22/01853) and European Union-NextGenerationEU (PMP21/00112) (to J.C.)., With funding form the Spanish government through the "Severa Ochoa Centre of Excellence" accreditation (CEX2021-001136-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A resurrected ancestor of Cas12a expands target access and substrate recognition for nucleic acid editing and detection

  • Jabalera, Ylenia
  • Tascón, Igor
  • Samperio, Sara
  • López-Alonso, Jorge P.
  • Gonzalez-Lopez, Monika
  • Aransay, Ana M.
  • Abascal-Palacios, Guillermo
  • Beisel, Chase L.
  • Ubarretxena-Belandia, Iban
  • Pérez-Jiménez, Raúl
The properties of Cas12a nucleases constrict the range of accessible targets and their applications. In this study, we applied ancestral sequence reconstruction (ASR) to a set of Cas12a orthologs from hydrobacteria to reconstruct a common ancestor, ReChb, characterized by near-PAMless targeting and the recognition of diverse nucleic acid activators and collateral substrates. ReChb shares 53% sequence identity with the closest Cas12a ortholog but no longer requires a T-rich PAM and can achieve genome editing in human cells at sites inaccessible to the natural FnCas12a or the engineered and PAM-flexible enAsCas12a. Furthermore, ReChb can be triggered not only by double-stranded DNA but also by single-stranded RNA and DNA targets, leading to non-specific collateral cleavage of all three nucleic acid substrates with similar efficiencies. Finally, tertiary and quaternary structures of ReChb obtained by cryogenic electron microscopy reveal the molecular details underlying its expanded biophysical activities. Overall, ReChb expands the application space of Cas12a nucleases and underscores the potential of ASR for enhancing CRISPR technologies., This work has been supported by grants PID2019-109087RB-I00 and PID2022-141347OB-I00 to R.P.-J.; PID2019-104423GB-I00 and PID2022-143177NB-I00 to I.U.-B.; and PID2021-126263OA-I00 to G.A.-P., funded by the Spanish Ministry of Science and Innovation (MICIU/AEI/10.13039/501100011033). This project has received funding from the European Union’s Horizon 2020 Research and Innovation Program under grant agreement number 964764 to R.P.-J. and from a European Research Council Consolidator Award (grant agreement number 865973) to C.L.B. The content presented in this paper represents the views of the authors, and the European Commission has no liability with respect to the content. Y.J. acknowledges financial support from Juan de la Cierva program grant FJC2021-047689-I, funded by the Spanish Ministry of Science and Innovation (MICIU/AEI/10.13039/501100011033) and by European Union NextGenerationEU/PRTR. R.P.-J. and Y.J. acknowledge financial support from the Spanish Foundation for the Promotion of Research of Amyotrophic Lateral Sclerosis (FUNDELA). J.P.L.-A. acknowledges financial support from a PTA contract granted by the MCIN/AEI. CIC bioGUNE support was provided from the Department of Industry, Tourism and Trade of the Government of the Autonomous Community of the Basque Country (Elkartek Research Programs 2020–2023), the Innovation Technology Department of the Bizkaia County and MINECO for the Severo Ochoa Center of Excellence Accreditation (CEX2021-001136-S). CIBERehd is funded by the Instituto de Salud Carlos III. High-resolution cryo-EM data collection was performed at the Basque Resource for Electron Microscopy, supported primarily by the Department of Education and the Innovation Fund of the Basque Government, the Fundación Biofísica Bizkaia and the Spanish Ministry of Science and Innovation, through the Plan de Recuperación, Transformación y Resiliencia (PRTR), funded by the NextGenerationEU (PRTR-C17.I1) program., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Polyamine-dependent metabolic shielding regulates alternative splicing

  • Zabala-Letona, Amaia
  • Pujana-Vaquerizo, Mikel
  • Martínez-Laosa, Belén
  • Ponce-Rodríguez, María
  • García-Longarte, Saioa
  • Mendizabal, Isabel
  • Gimeno, Ana
  • Rogalska, Malgorzata
  • Tan, Joycelyn
  • Cabrera, Diana
  • van Liempd, Sebastiaan
  • Ximenez-Embun, Pilar
  • Espinosa, Sergio
  • Fagoaga-Eugui, Maider
  • Peccati, Francesca
  • Zakrzewski, Maciej
  • Astobiza, Ianire
  • Arana-Castañares, Mikel
  • Cherkaoui, Sarah
  • Sendino, Maria
  • Martín-Barros, Inés
  • Ercilla, Amaia
  • Bozal-Basterra, Laura
  • Carlevaris, Onintza
  • Arruabarrena-Aristorena, Amaia
  • Pérez-Andrés, Encarnación
  • Santamaria-Zamorano, Telmo
  • Ferrer-Bonsoms, Juan A.
  • Carazo, Fernando
  • Ciesla, Maciej
  • Lobato, Cesar
  • Seoane, Joan
  • Martín-Martín, Natalia
  • Barrio, Rosa
  • Sutherland, James D.
  • Aransay, Ana M.
  • Falcón-Pérez, Juan Manuel
  • Martínez-Pastor, Barbara
  • Rubio, Angel
  • Blanco, Francisco J.
  • Hogarty, Michael D.
  • Morscher, Raphael J.
  • Berra, Edurne
  • Serwa, Remigiusz A.
  • Jiménez-Barbero, Jesús
  • Jiménez-Osés, Gonzalo
  • Efeyan, Alejo
  • Finley, Lydia
  • Lizcano, Jose M.
  • Muñoz, Javier
  • Valcarcel, Juan
  • Carracedo, Arkaitz
40 páginas, figuras y material suplementario., Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1-3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding., The work of A.C. is supported by the MICIU (PID2022-141553OB-I0 (FEDER/EU), BBVA foundation Leonardo Grant for Scientific Research and Cultural Creation (Beca Leonardo LEO23-2-10984-BBM-TRA-261), Fundación Cris Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation (CEX2021-001136-S), Fundación AECC (Excelencia 2024 call, Premetacan—EPAEC246710BIO), Fundación Occident, Astrazeneca Foundation (Young Oncologist award), Vencer el Cáncer Foundation, Mondravember, iDIFFER Network of Excellence (RED2022-134792-T; RED2024-153635-T), and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and ISCIII. A.Z.-L. is supported by AECC (INVES223210ZABA). M.P.-V. was supported by a Basque Government PhD training fellowship and CIBER. B.M.-L. and M.A.-C. were supported by FPI fellowships (MCIU). M.F.-E. was supported by Basque Government PhD training fellowship. A. Ercilla is supported by a Juan de la Cierva Incorporación fellowship from the MCIN/AEI /10.13039/501100011033. L.B.-B. was supported by the AECC Foundation (POSTD19048BOZA). M.Z. and R.A.S. are supported by the National Science Centre, Poland (grant no. 2020/38/E/ST4/00250). I.M. is supported by Fundación Cris Contra el Cáncer (PR_TPD_2020-19) and a Ramón y Cajal contract (RYC2023-044682-I) funded by the MCIU. G.J.-O. was funded by the MICIU (PID2021-125946OB-I00 and PDC2022-133725-C22). F.P. was funded by the MICIU (IJC2020-045506-I) and RYC (RYC2022-036457-I). F.J.B. was funded by PID2023-147699OB-I00 grant from AEI- /10.13039/501100011033. The work of A.R. is partially supported by the Basque Department of Industry, Tourism and Trade (Elkartek). The laboratory of J.M. is supported by the European Union Horizon 2020 programme INFRAIA project EPIC-XS (project 823839). S.C. and R.J.M. were supported by grants from the NOMIS Foundation and Geistlich-Stucki Stiftung. R.B. and J.D.S. were funded by PID2020-114178GB-I00 and PID2023-147399NB-I00 (MINECO /MICINN/FEDER, EU). E.B. is supported by the PID2022-141556OB-I00 (FEDER/EU) and RED2022-134407-T). A. Efeyan is funded by grant PID2022-136413OB-I00. The laboratory of J.M.L. is funded by the MICIU (PID2022-136391OB-I00). The work of L.F. was supported by Memorial Sloan Cancer Center Support Grant P30CA008748. The work from R.J.M. in this publication is based on work from COST Action Translational control in Cancer European Network (TRANSLACORE) CA21154 supported by COST (European Cooperation in Science and Technology). M.D.H. was supported by a US Department of Defense Team Translational Science Award (CA170257)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gut microbiota and immunometabolism in obesity

  • Torres Mayo, Alba
  • Liébana García, Rebeca
  • Olivares, Marta
  • Pellón, Aize
  • Anguita, Juan
  • Sanz Herranz, Yolanda
The gut microbiota plays a central role in modulating both immunity and metabolism. Obesity-associated microbiota configuration is a critical driver of persistent inflammatory activation and immune dysfunction, ultimately leading to chronic metabolic disorders. Immunometabolism examines how metabolic demands shape immune cell function and how immune responses influence cellular metabolism. Emerging research on how the gut microbiota contribute to immune cell metabolic processes and the resulting health outcomes is deepening our understanding of the mechanisms underlying obesity and metabolic diseases. In this review, we summarize how intracellular metabolic pathways and master regulators, such as mTOR and AMPK, orchestrate immune cell function and how their dysregulation contributes to obesity-associated immune and metabolic dysfunction. We also discuss how gut microbiota influences the immunometabolism of different myeloid and lymphoid cell subsets and intestinal epithelial cells. Finally, we review the role of microbially produced metabolites, including short-chain fatty acids, lactate, succinate, bile acids, and amino acids, in reprogramming immune cell metabolism. We also discuss whether modulating gut microbiota function to regulate immunometabolic pathways could help restore immune homeostasis and reduce obesity-related complications., This study has been funded by the Spanish Ministry of Science, Innovation and Universities (MCIU; grant PID2023-150693OB-I00 to YS, PID2024-155763OB-I00 to JA), and the “Severo Ochoa” grant of the National Agency for Research (AEI)- MCIU (Ref. CEX2021-001189-S to IATA-CSIC, CEX2021-001136-S to CIC bioGUNE). The predoctoral contract to A. T-M from MCIU is acknowledged. AP is supported by an MSCA Postdoctoral Fellowship (award number 101150747)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S and CEX2021-001136-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tertiary and quaternary structure remodeling by occupancy of the substrate binding pocket in a large glutamate dehydrogenase

  • Lázaro, Melisa
  • Chamorro, Nicolás
  • López-Alonso, Jorge P.
  • Charro, Diego
  • Rasia, Rodolfo M.
  • Jiménez-Osés, Gonzalo
  • Valle, Mikel
  • Lisa, María-Natalia
[Data Availability Statement] Cryo-EM maps obtained for mL-GDH180 were deposited in the Electron Microscopy Data Bank under the accession codes EMD-52419 (Open), EMD-52420 (Closed1), EMD-52421 (Closed2), EMD-52422 (empty-monomer), EMD-52423 (cofactor-monomer), EMD-52424 (cofactor/ligand-monomer), EMD-52425 (Open-cofactor/ligand-monomer), EMD-52426 (Closed1-cofactor/ligand-monomer), EMD-52427 (Closed2-cofactor/ligand-monomer), EMD-52428 (total-monomer) and EMD-52429 (Closed2-cofactor/ligand-tetramer). Atomic coordinates were deposited in the Protein Data Bank under the accession codes 9HUX (Open), 9HUY (Closed1), 9HUZ (Closed2), 9HV0 (empty-monomer), 9HV4 (cofactor-monomer), 9HV5 (cofactor/ligand-monomer) and 9HV6 (total-monomer)., Glutamate dehydrogenases (GDHs) catalyze the oxidative deamination of L-glutamate to 2-oxoglutarate using NAD(P)+ as a cofactor. The large type of GDHs (L-GDHs) displays a dynamic homotetrameric architecture that alternates between open and closed states. However, the catalytic mechanism and the functional relevance of the large conformational changes in L-GDHs remain poorly understood. Here, we use cryo-EM to investigate the structure and the conformational landscape of the mycobacterial L-GDH composed of 180 kDa subunits (mL-GDH180) when incubated with L-glutamate and NAD+. Classification of the heterogeneous population of tetramers reveals opening-closing motions and sorting of individual subunits resolves the occupancy of the cofactor and substrate binding pockets. Cryo-EM maps show that ligand binding to the glutamate binding pocket is accompanied by structural changes in a region approximately two nanometers away from the active site, leading to the formation of a previously undetected interaction between the catalytic domains of neighboring subunits in mL-GDH180 closed tetrameric states. Our findings indicate that the occupancy of the substrate binding site of mL-GDH180 is linked to a remodeling of both the tertiary and quaternary structure of the enzyme., This work was supported by grants PICT 2019-00989 and PICT 2021-00253 from the Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación (Agencia I + D + i, Argentina) to MNL as well as grants PID2021-124074NB-I00 and PID2021-125946OB-I00 from Agencia Estatal de Investigación of Spain to MV and GJO, respectively. We also thank the Severo Ochoa Center of Excellence Accreditation CEX2021-001136-S. MNL and RMR are career investigators from Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET, Argentina). NC holds a CONICET PhD fellowship. Some of this work was performed at the Basque Resource for Electron Microscopy located at Instituto Biofisika (UPV/EHU, CSIC), supported by the Department of Science, Universities and Innovation and the Innovation Fund of the Basque Government, with additional support from MCIN (Recovery, Transformation and Resilience Plan) and the Basque Government “Biotechnology Complementary Plan Applied to Health” with funding from European Union NextGenerationEU (PRTR-C17.I1; PRTR-C17.I01.P01.S13) (AAAA_ACG_AY_2539/22_05)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Overexpression of bank vole PrP(I109) in mice induces a spontaneous atypical prion disease with sex-dependent onset, early NfL elevation, and universal prion strain permissiveness

  • Eraña, Hasier
  • Vidal, Enric
  • Fernández-Borges, N.
  • Charco, Jorge M.
  • Díaz‑Domínguez, Carlos M.
  • Sampedro-Torres-Quevedo, Cristina
  • San-Juan-Ansoleaga, Maitena
  • Fernández-Muñoz, Eva
  • Galarza-Ahumada, Josu
  • Pérez-Castro, Miguel A.
  • Gonçalves-Anjo, Nuno
  • Piñeiro, Patricia
  • Pirisinu, Laura
  • di Bari, Michele
  • Giler, Samanta
  • Raimondi, Ilaria
  • Espinosa, Juan Carlos
  • Vanni, Ilaria
  • D’Agostino, Claudia
  • Rodríguez-Cuesta, Juan
  • Pasetto, Laura
  • Bonetto, Valentina
  • González-Martín, Nora
  • Teijeira, Susana
  • Zou, Wen-Quan
  • Geijo, Mariví
  • Torres, Juan María
  • Chiesa, Roberto
  • Sánchez‑Martín, Manuel A.
  • Nonno, Romolo
  • Requena, Jesús R.
  • Castilla, Joaquín
Transgenic mice overexpressing bank vole prion protein with the isoleucine 109 polymorphism, TgVole(I109)4x, develop spontaneous neurodegenerative disease with sex-dependent onset, averaging 170 days in females and 200 days in males at terminal stage. The clinical and pathological features closely resemble Gerstmann-Sträussler-Scheinker syndrome (GSS), with characteristic ataxia, dysmetria, kyphosis, and prominent PrP plaques. Biochemical analysis reveals an atypical prion protein banding pattern with a distinctive low molecular weight band (7–10 kDa) following proteinase K digestion, similar to other atypical prion diseases such as small ruminants atypical scrapie (AS). Importantly, these spontaneously generated prions are highly infectious when passaged to mice expressing the same I109 polymorphism as well as to wild bank voles carrying the I109 polymorphism, but not to models expressing the methionine variant at this position, demonstrating the critical role of this specific polymorphism in atypical prion propagation. Temporal analysis reveals that infectious prions emerge significantly (2–3 months) before clinical signs appear, offering important insights into the pre-clinical phase of prion diseases. Serum neurofilament light chain levels increase significantly at 80 days of age, approximately 100 days before clinical onset, providing a wide therapeutic window with a reliable biomarker. The TgVole(I109)4× model exhibits extraordinary versatility in propagating diverse prion strains, showing remarkable susceptibility to atypical prions (including GSS and AS) with exceptionally short incubation periods, while maintaining the ability to efficiently propagate classical and recombinant prion strains. We present here a thoroughly characterized transgenic mouse model that spontaneously develops an atypical, bona fide prion disease with sex-related differences in disease onset. This model offers valuable insights into spontaneous and atypical prionopathies while demonstrating exceptional versatility for studying diverse prion strains and potential utility for evaluating therapeutic interventions when used with appropriate study designs that account for individual variability., The present work was partially funded by five different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21 granted to J.C., PID2021-1222010B-C22 granted to E.V., and PID2023-146146NB-I00 to J.C.E. funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), UE and PID2020-117465GB-I00 granted to J.R.R., funded by MICIU/AEI/https://doi.org/10.13039/501100011033. EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027) granted to J.C. and H.E. Additional support was provided by the Instituto de Salud Carlos III (ISCIII), grant numbers AC21_2/00024 (granted to J.C), and JPND-2023–1822-108 (granted to R.C.) as part of the JPND initiative JPND-2021–650-130. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to J.C., also funded by Ministerio de Ciencia e Innovación/AEI /https://doi.org/10.13039/501100011033. E.F.-M. received funding from Fundación Tatiana Pérez de Guzmán el Bueno, grant BN661-FTPGB-2023. Transgenic Facility, directed by M.A.S.-M., is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. This work also received funding from the Creutzfeldt-Jakob Disease Foundation—2022. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., With funding form the Spanish government through the "Severa Ochoa Centre of Excellence" accreditation (CEX2021-001136-S)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Overexpression of bank vole PrP(I109) in mice induces a spontaneous atypical prion disease with sex-dependent onset, early NfL elevation, and universal prion strain permissiveness

  • Eraña, Hasier
  • Vidal, Enric
  • Fernández-Borges, Natalia
  • Charco, Jorge M.
  • Díaz‑Domínguez, Carlos M.
  • Sampedro-Torres-Quevedo, Cristina
  • San-Juan-Ansoleaga, Maitena
  • Fernández-Muñoz, Eva
  • Galarza-Ahumada, Josu
  • Pérez-Castro, Miguel Ángel
  • Gonçalves-Anjo, Nuno
  • Piñeiro, Patricia
  • Pirisinu, Laura
  • Di Bari, Michele Angelo
  • Giler, Samanta
  • Raimondi, Ilaria
  • Espinosa, Juan Carlos
  • Vanni, Ilaria
  • D’Agostino, Claudia
  • Rodríguez-Cuesta, Juan
  • Pasetto, Laura
  • Bonetto, Valentina
  • González-Martín, Nora
  • Teijeira, Susana
  • Zou, Wen-Quan
  • Geijo, Mariví
  • Torres, Juan María
  • Chiesa, Roberto
  • Sánchez‑Martín, Manuel A.
  • Nonno, Romolo
  • Requena, Jesús R.
  • Castilla, Joaquín
Transgenic mice overexpressing bank vole prion protein with the isoleucine 109 polymorphism, TgVole(I109)4x, develop spontaneous neurodegenerative disease with sex-dependent onset, averaging 170 days in females and 200 days in males at terminal stage. The clinical and pathological features closely resemble Gerstmann-Sträussler-Scheinker syndrome (GSS), with characteristic ataxia, dysmetria, kyphosis, and prominent PrP plaques. Biochemical analysis reveals an atypical prion protein banding pattern with a distinctive low molecular weight band (7–10 kDa) following proteinase K digestion, similar to other atypical prion diseases such as small ruminants atypical scrapie (AS). Importantly, these spontaneously generated prions are highly infectious when passaged to mice expressing the same I109 polymorphism as well as to wild bank voles carrying the I109 polymorphism, but not to models expressing the methionine variant at this position, demonstrating the critical role of this specific polymorphism in atypical prion propagation. Temporal analysis reveals that infectious prions emerge significantly (2–3 months) before clinical signs appear, offering important insights into the pre-clinical phase of prion diseases. Serum neurofilament light chain levels increase significantly at 80 days of age, approximately 100 days before clinical onset, providing a wide therapeutic window with a reliable biomarker. The TgVole(I109)4× model exhibits extraordinary versatility in propagating diverse prion strains, showing remarkable susceptibility to atypical prions (including GSS and AS) with exceptionally short incubation periods, while maintaining the ability to efficiently propagate classical and recombinant prion strains. We present here a thoroughly characterized transgenic mouse model that spontaneously develops an atypical, bona fide prion disease with sex-related differences in disease onset. This model offers valuable insights into spontaneous and atypical prionopathies while demonstrating exceptional versatility for studying diverse prion strains and potential utility for evaluating therapeutic interventions when used with appropriate study designs that account for individual variability., The present work was partially funded by five different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21 granted to J.C., PID2021-1222010B-C22 granted to E.V., and PID2023-146146NB-I00 to J.C.E. funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), UE and PID2020-117465GB-I00 granted to J.R.R., funded by MICIU/AEI/https://doi.org/10.13039/501100011033. EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027) granted to J.C. and H.E. Additional support was provided by the Instituto de Salud Carlos III (ISCIII), grant numbers AC21_2/00024 (granted to J.C), and JPND-2023–1822-108 (granted to R.C.) as part of the JPND initiative JPND-2021–650-130. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to J.C., also funded by Ministerio de Ciencia e Innovación/AEI /https://doi.org/10.13039/501100011033. E.F.-M. received funding from Fundación Tatiana Pérez de Guzmán el Bueno, grant BN661-FTPGB-2023. Transgenic Facility, directed by M.A.S.-M., is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. This work also received funding from the Creutzfeldt-Jakob Disease Foundation—2022. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The L108I polymorphism in mouse prion protein drives spontaneous disease and enhances transmission of atypical and classical prion strains

  • Eraña, Hasier
  • Vidal, Enric
  • Fernández-Borges, Natalia
  • Charco, Jorge M
  • Díaz-Domínguez, Carlos M
  • Sampedro-Torres-Quevedo, Cristina
  • Galarza-Ahumada, Josu
  • Fernández-Muñoz, Eva
  • San-Juan-Ansoleaga, Maitena
  • Pérez-Castro, Miguel Ángel
  • Gonçalves-Anjo, Nuno
  • Piñeiro, Patricia
  • Giler, Samanta
  • González-Martín, Nora
  • Lorenzo, Nuria L.
  • Manero-Azua, Africa
  • de Nanclares, Guiomar P.
  • Geijo, Mariví
  • Sánchez-Martín, Manuel A
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion diseases are fatal neurodegenerative disorders that can be idiopathic, associated with genetic mutations, or acquired by infection with misfolded prion protein. We developed two complementary transgenic mouse models to investigate how the L108I substitution in mouse prion protein (PrP) influences spontaneous prion formation and transmission characteristics. The transgenic mouse model overexpressing the variant at approximately three times wild-type (WT) PrP levels (TgMo(L108I)3x) consistently developed a spontaneous neurodegenerative disorder between 219 and 536 days of age with 100% penetrance. This spontaneous disease exhibited biochemical and neuropathological characteristics of atypical prion disorders, featuring a distinctive 7–10 kDa protease-resistant PrP fragment and pathology comparable to small ruminants' atypical scrapie and certain forms of Gerstmann–Sträussler–Scheinker syndrome (GSS). In contrast, the knock-in model expressing the same variant at physiological levels (TgMo(L108I)1x) showed no spontaneous disease beyond 600 days, demonstrating that both the specific amino acid substitution and elevated expression levels are necessary for spontaneous prion formation. The spontaneously generated prions transmitted efficiently to models expressing the I108 variant and to Tga20 mice overexpressing WT PrP but encountered a robust transmission barrier toward WT mice, indicating strain-specific replication requirements. The TgMo(L108I)3x model demonstrated exceptional versatility as a universal acceptor for heterogeneous prion isolates, demonstrating superior efficiency in propagating atypical variants like GSS A117V (57 ± 0.6 days) and rapid propagation of classical scrapie-derived mouse prion strains, including Rocky Mountains Laboratory mouse prion strain (RML) (85 ± 3.8 days) and 22L (95 ± 1 days). Comparative analysis revealed that the L108I substitution differentially impacts strain propagation, with greater acceleration of RML (~33% shorter incubation) than 22L (~0.5% shorter) compared to WT mice. These complementary systems offer powerful experimental platforms for investigating the molecular determinants of spontaneous prion formation, strain selection and transmission barriers, providing insights into idiopathic prion pathogenesis and developing therapeutic interventions., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21 granted to Joaquín Castilla, PID2020-117465GB-I00 granted to Jesús R. Requena, and PID2021-1222010B-C22 granted to Enric Vidal, funded by MCIN/AEI/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027) granted to Joaquín Castilla, Hasier Eraña and Enric Vidal. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to Joaquín Castilla, also funded by Ministerio de Ciencia e Innovación/AEI/10.13039/501100011033. Transgenic Facility of IBSAL-University of Salamanca, directed by Manuel A. Sánchez‑Martín, is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. Eva Fernández-Muñoz received funding from Fundación Tatiana Pérez de Guzmán el Bueno, grant BN661-FTPGB-2023. This work also received funding from the Creutzfeldt-Jakob Disease Foundation—2022. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Understanding the key features of the spontaneous formation of bona fde prions through a novel methodology that enables their swift and consistent generation

  • Eraña, Hasier
  • Díaz‑Domínguez, Carlos M.
  • Charco, Jorge M.
  • Vidal, Enric
  • González‑Miranda, Ezequiel
  • Pérez‑Castro, Miguel A.
  • Piñeiro, Patricia
  • López‑Moreno, Rafael
  • Sampedro‑Torres‑Quevedo, Cristina
  • Fernández‑Veiga, Leire
  • Tasis‑Galarza, Juan
  • Lorenzo, Nuria L.
  • Santini‑Santiago, Aileen
  • Lázaro, Melisa
  • García‑Martínez, Sandra
  • Gonçalves‑Anjo, Nuno
  • San‑Juan‑Ansoleaga, Maitena
  • Galarza‑Ahumada, Josu
  • Fernández‑Muñoz, Eva
  • Giler, Samanta
  • Valle, Mikel
  • Telling, Glenn C.
  • Geijó, Mariví
  • Requena, Jesús R.
  • Castilla, Joaquín
Among transmissible spongiform encephalopathies or prion diseases afecting humans, sporadic forms such as spo‑ radic Creutzfeldt–Jakob disease are the vast majority. Unlike genetic or acquired forms of the disease, these idiopathic forms occur seemingly due to a random event of spontaneous misfolding of the cellular PrP (PrPC) into the patho‑ genic isoform (PrPSc). Currently, the molecular mechanisms that trigger and drive this event, which occurs in approximately one individual per million each year, remain completely unknown. Modelling this phenomenon in experimental settings is highly challenging due to its sporadic and rare occurrence. Previous attempts to model spontaneous prion misfolding in vitro have not been fully successful, as the spontaneous formation of prions is infre‑ quent and stochastic, hindering the systematic study of the phenomenon. In this study, we present the frst method that consistently induces spontaneous misfolding of recombinant PrP into bona fde prions within hours, providing unprecedented possibilities to investigate the mechanisms underlying sporadic prionopathies. By fne‑tuning the Pro‑ tein Misfolding Shaking Amplifcation method, which was initially developed to propagate recombinant prions, we have created a methodology that consistently produces spontaneously misfolded recombinant prions in 100% of the cases. Furthermore, this method gives rise to distinct strains and reveals the critical infuence of charged sur‑ faces in this process., The present work was partially funded by three different grants awarded by “Ministerio de Economía y Competitividad” (Spanish Government), grant numbers PID2021-122201OB-C21, PID2021-1222010B-C22 and PID2020-117465GB-I00, funded by MCIN/AEI/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), and by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S, also funded by MCIN/AEI/10.13039/501100011033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Effect of primary structural variation on cervid prion protein in flexibility, stability, and spontaneous misfolding propensity

  • Díaz-Domínguez, Carlos M.
  • Eraña, Hasier
  • Peccati, Francesca
  • Vidal, Enric
  • Charco, Jorge M.
  • Sampedro-Torres-Quevedo, Cristina
  • Pérez-Castro, Miguel A.
  • Lorenzo, Nuria L.
  • Giler, Samanta
  • Telling, Glenn C.
  • Geijo, Mariví
  • Requena, Jesús R.
  • Jiménez-Osés, Gonzalo
  • Castilla, Joaquín
Protein misfolding is central to numerous neurodegenerative disorders, collectively known as proteinopathies, which include Alzheimer's disease, Parkinson's disease, and prion diseases, among others. In many cases, specific polymorphisms of the proteins associated with these diseases influence their misfolding. However, the precise ways in which these polymorphisms affect protein integrity and how they contribute to misfolding propensity remain unclear. In the case of prion diseases, they are caused by prions or PrPSc, the misfolded isoforms of the cellular prion protein (PrPC). Chronic Wasting Disease (CWD) is a prion disease that affects cervids and can exhibit lymphotropic properties, making it the most widespread proteinopathy. For that reason, cervid PrPs and their polymorphisms have been extensively studied. To better understand the role of these polymorphisms, we analyzed 45 cervid PrP variants to assess their effects on flexibility, stability, and spontaneous misfolding propensity. The cervid variants were expressed as recombinant PrP in E. coli and were analyzed for thermal stability using circular dichroism. Additionally, the rec-PrPs served as substrates for Protein Misfolding Shaking Amplification (PMSA), enabling assessment of each variant's spontaneous misfolding propensity. This process led to the formation of bona fide prions, as confirmed by inoculation of one of the resulting conformers into transgenic mice expressing bank vole PrP. In parallel, molecular dynamics simulations were conducted to analyze the structural flexibility of the variants. While differences in protein flexibility were observed, no correlation was detected among flexibility, thermal stability, and the observed variable spontaneous misfolding propensity, suggesting that these properties are independent parameters., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21, PID2021-1222010B-C22, and PID2020-117465GB-I00, funded by MCIN/AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). Also funded by MCIN/AEI /10.13039/501100011033, F.P. and G.J.O. were provided with the grants RYC2022-036457-I and PID2021-125946OB-I00, respectively. EFA031/01 NEURO-COOP, which is co-funded at 65 % by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021-2027). Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, as part of a grant from the European Joint Program for Neurodegenerative Research (JPND) JPND-2021-650-130. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S, also funded by MCIN/AEI /10.13039/501100011033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cofactors facilitate bona fide prion misfolding in vitro but are not necessary for the infectivity of recombinant murine prions

  • Pérez-Castro, Miguel Ángel
  • Eraña, Hasier
  • Vidal, Enric
  • Charco, Jorge M.
  • Lorenzo, Nuria L.
  • Gonçalves-Anjo, Nuno
  • Galarza-Ahumada, Josu
  • Díaz-Domínguez, Carlos M.
  • Piñeiro, Patricia
  • González-Miranda, Ezequiel
  • Giler, Samanta
  • Telling, Glenn
  • Sánchez-Martín, Manuel A.
  • Garrido, Joseba
  • Geijo, Mariví
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion diseases, particularly sporadic cases, pose a challenge due to their complex nature and heterogeneity. The underlying mechanism of the spontaneous conversion from PrPC to PrPSc, the hallmark of prion diseases, remains elusive. To shed light on this process and the involvement of cofactors, we have developed an in vitro system that faithfully mimics spontaneous prion misfolding using minimal components. By employing this PMSA methodology and introducing an isoleucine residue at position 108 in mouse PrP, we successfully generated recombinant murine prion strains with distinct biochemical and biological properties. Our study aimed to explore the influence of a polyanionic cofactor in modulating strain selection and infectivity in de novo-generated synthetic prions. These results not only validate PMSA as a robust method for generating diverse bona fide recombinant prions but also emphasize the significance of cofactors in shaping specific prion conformers capable of crossing species barriers. Interestingly, once these conformers are established, our findings suggest that cofactors are not necessary for their infectivity. This research provides valuable insights into the propagation and maintenance of the pathobiological features of cross-species transmissible recombinant murine prion and highlights the intricate interplay between cofactors and prion strain characteristics., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21 granted to J.C., PID2021-1222010B-C22 granted to E.V., and PID2020-117465GB-I00 granted to J.R.R., funded by MCIN/ AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021-2027) granted to J.C. and H.E. Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, granted to J.C. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to J.C., also funded by Ministerio de Ciencia e Innovación/AEI /10.13039/501100011033. Transgenic Facility, directed by M.A.S.-M., is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Rapid generation of prion disease models using AAV-delivered PrP variants in knockout mice

  • San-Juan-Ansoleaga, Maitena
  • Fernández-Muñoz, Eva
  • Charco, Jorge M.
  • Vidal, Enric
  • Herrero-Martínez, Diego
  • Galarza-Ahumada, Josu
  • Sampedro-Torres-Quevedo, Cristina
  • Giler, Samanta
  • Geijo, Mariví
  • González-Aseguinolaza, Gloria
  • Eraña, Hasier
  • Castilla, Joaquín
The study of prion biology has traditionally relied on transgenic mouse models, which, while valuable, require significant time and resources to develop. Here, we present a rapid and flexible alternative using adeno-associated virus (AAV) vectors to express modified prion proteins in PrP-knockout (PrP-KO) mice. Through systematic evaluation of multiple AAV constructs, we optimized vector design by comparing different CNS-specific promoters and regulatory elements to generate prion disease models capable of faithfully propagating the inoculated prion strain. We identified an optimized AAV construct incorporating the human synapsin promoter, MVM enhancer, and WPRE posttranscriptional regulatory element encapsidated in the AAV9P31 serotype to drive neuron-specific expression of modified mouse PrP (W144Y epitope) and bank vole I109 PrP (W145Y epitope). Following intravenous administration, we achieved brain-wide expression at levels comparable to or even exceeding endogenous PrP in some regions. When challenged with mouse-adapted RML prions or human Gerstmann-Sträussler-Scheinker (GSS-A117V) disease-causing prions, AAV-PrP mice developed characteristic signs of prion disease with accelerated kinetics (58–106 days post-inoculation for RML; 105–112 dpi for GSS-A117V), displaying features typical of each strain. Serial transmission of AAV-generated RML prions to wild-type mice confirmed preservation of strain-specific properties (165 ± 4 dpi), validating the authenticity of prion propagation in this system. This approach provides a versatile platform for rapidly generating and studying prion variants in an authentic brain environment. By reducing model generation time from months to weeks, this system enables accelerated investigation of prion structure–function relationships, strain properties, and therapeutic strategies, with potential applications extending to other protein misfolding diseases., The present work was partially funded by four grants awarded by the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (Spanish Government): grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21, and PID2021-122201OB-C22, funded by MCIN/AEI/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF); and grant EFA031/01 NEURO-COOP, co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021-2027). Additional support was provided by the CJD Foundation (2024 grant). CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation (CEX2021-001136-S), funded by MCIN/AEI/10.13039/501100011033. Additionally, Eva Fernández-Muñoz received funding from Fundacion Tatiana Perez de Guzman el Bueno, PhD grant BN661-FTPGB-2023. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A Protein Misfolding Shaking Amplificationbased method for the spontaneous generation of hundreds of bona fide prions

  • Eraña, Hasier
  • Sampedro-Torres-Quevedo, Cristina
  • Charco, Jorge M.
  • Díaz-Domínguez, Carlos M.
  • Peccati, Francesca
  • San-Juan-Ansoleaga, Maitena
  • Vidal, Enric
  • Gonçalves-Anjo, Nuno
  • Pérez-Castro, Miguel A.
  • González-Miranda, Ezequiel
  • Piñeiro, Patricia
  • Fernández-Veiga, Leire
  • Galarza-Ahumada, Josu
  • Fernández-Muñoz, Eva
  • Perez de Nanclares, Guiomar
  • Telling, Glenn
  • Geijo, Mariví
  • Jiménez-Osés, Gonzalo
  • Castilla, Joaquín
Prion diseases are a group of rapidly progressing neurodegenerative disorders caused by the misfolding of the endogenous prion protein (PrPC) into a pathogenic form (PrPSc). This process, despite being the central event underlying these disorders, remains largely unknown at a molecular level, precluding the prediction of new potential outbreaks or interspecies transmission incidents. In this work, we present a method to generate bona fide recombinant prions de novo, allowing a comprehensive analysis of protein misfolding across a wide range of prion proteins from mammalian species. We study more than 380 different prion proteins from mammals and classify them according to their spontaneous misfolding propensity and their conformational variability. This study aims to address fundamental questions in the prion research field such as defining infectivity determinants, interspecies transmission barriers or the structural influence of specific amino acids and provide invaluable information for future diagnosis and therapy applications., The authors would like to thank the following for their support: IKERBasque foundation, personnel from vivarium, IT service (in particular to Sara Gómez Ramos for her assistance with the PrPdex webpage), maintenance departments of CIC bioGUNE, Neiker and IRTA-CReSA. The authors would also like to acknowledge the work from past laboratory members of the Prion Research Lab from CIC bioGUNE, that despite not directly involved in the manuscript have contributed along the years to the development of all the methods and techniques currently used in the laboratory (specially to Tomás Barrio and Leire Hervá for their efforts at the initial and end stages of the work, respectively). Finally, we would like to thank Jesús R. Requena for always useful scientific discussions and advice. The present work was partially funded by different grants awarded by “Ministerio de Economía y Competitividad” (Spanish Government), grant numbers PID2021-122201OB-C21, PID2021-1222010BC22, PID2021-125946OB-I00 and IJC2020-045506-I, funded by MCIN/ AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), and by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, to J.C. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021- 001136-S, also funded by MCIN/AEI /10.13039/501100011033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Conservation of strain properties of bank vole-adapted chronic wasting disease in the absence of glycosylation and membrane anchoring

  • Vidal, Enric
  • Eraña, Hasier
  • Charco, Jorge M.
  • Lorenzo, Nuria L.
  • Giler, Samanta
  • Ordóñez, Montserrat
  • Fernández-Muñoz, Eva
  • San-Juan-Ansoleaga, Maitena
  • Telling, Glenn C.
  • Sánchez-Martín, Manuel A.
  • Geijo, Mariví
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion disease phenotypes (prion strains) are primarily determined by the specific misfolded conformation of the cellular prion protein (PrPC). However, post-translational modifications, including glycosyl phosphatidyl inositol (GPI) membrane anchoring and glycosylation, may influence strain characteristics. We investigated whether these modifications are essential for maintaining the unique properties of bank vole-adapted Chronic Wasting Disease (CWD-vole), the fastest known prion strain. Using a novel transgenic mouse model expressing I109 bank vole PrPC lacking the GPI anchor and largely devoid of glycans, we performed serial passages of CWD-vole prions. Despite elongated initial incubation periods, the strain maintained 100 % attack rate through three passages. Although the pathological phenotype showed characteristic GPI-less features, including abundant extracellular plaque formation, three subsequent serial passages in fully glycosylated and GPI-anchored bank vole I109 PrPC expressing transgenic mice TgVole (1×) demonstrated that the strain's distinctive rapid propagation properties were preserved. These findings suggest that neither GPI anchoring nor glycosylation are essential for maintaining CWD-vole strain properties, supporting the concept that strain characteristics are primarily encoded in the protein's misfolded structure., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21 and PID2021-1222010B-C22, and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65 % by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027). Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024 as member of a JPND grant JPND-2021-650-130. Additionally, CICbioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S, also funded by MCIN/AEI/10.13039/501100011033. Transgenic Facility, directed by M.A. S-M, is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Docta Complutense
Publicación Artículo científico (JournalArticle)

The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

  • Goikoetxea Usandizaga, Naroa
  • Bravo, Miren
  • Egia Mendikute, Leire
  • Abecia, Leticia
  • Serrano Maciá, Marina
  • Urdinguio, Rocío G.
  • Clos García, Marc
  • Rodríguez Agudo, Rubén
  • Araujo Legido, Raquel
  • López Bermudo, Lucía
  • Delgado, Teresa C.
  • Lachiondo Ortega, Sofía
  • González Recio, Irene
  • Gil Pitarch, Clàudia
  • Peña Cearra, Ainize
  • Simón, Jorge
  • Benede Ubieto, Raquel
  • Ariño, Silvia
  • Herranz, Jose M.
  • Azkargorta, Mikel
  • Salazar Bermeo, Julio
  • Martí, Nuria
  • Varela Rey, Marta
  • Falcón Pérez, Juan M.
  • Lorenzo, Óscar
  • Nogueiras, Rubén
  • Elortza, Félix
  • Nevzorova, Yulia
  • Cubero Palero, Francisco Javier
  • Saura, Domingo
  • Martínez Cruz, Luis Alfonso
  • Sabio, Guadalupe
  • Palazón, Asís
  • Sancho Bru, Pau
  • Elguezabal, Natalia
  • Fraga, Mario F.
  • Ávila, Matías A.
  • Bataller, Ramón
  • Marín, José J.G.
  • Martín, Franz
  • Martínez Chantar, María Luz
Background and Aims: Alcohol-associated liver disease (ALD) accounts for 70% of liver-related deaths in Europe, with no effective approved therapies. Although mitochondrial dysfunction is one of the earliest manifestations of alcohol-induced injury, restoring mitochondrial activity remains a problematic strategy due to oxidative stress. Here, we identify methylation-controlled J protein (MCJ) as a mediator for ALD progression and hypothesize that targeting MCJ may help in recovering mitochondrial fitness without collateral oxidative damage. Approach and Results: C57BL/6 mice [wild-type (Wt)] Mcj knockout and Mcj liver-specific silencing (MCJ-LSS) underwent the NIAAA dietary protocol (Lieber-DeCarli diet containing 5% (vol/vol) ethanol for 10 days, plus a single binge ethanol feeding at day 11). To evaluate the impact of a restored mitochondrial activity in ALD, the liver, gut, and pancreas were characterized, focusing on lipid metabolism, glucose homeostasis, intestinal permeability, and microbiota composition. MCJ, a protein acting as an endogenous negative regulator of mitochondrial respiration, is downregulated in the early stages of ALD and increases with the severity of the disease. Whole-body deficiency of MCJ is detrimental during ALD because it exacerbates the systemic effects of alcohol abuse through altered intestinal permeability, increased endotoxemia, and dysregulation of pancreatic function, which overall worsens liver injury. On the other hand, liver-specific Mcj silencing prevents main ALD hallmarks, that is, mitochondrial dysfunction, steatosis, inflammation, and oxidative stress, as it restores the NAD+/NADH ratio and SIRT1 function, hence preventing de novo lipogenesis and improving lipid oxidation. Conclusions: Improving mitochondrial respiration by liver-specific Mcj silencing might become a novel therapeutic approach for treating ALD.